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Background: Polypharmacy has no consensus definition in the literature. Previously used 
definitions include those based on the number of medications and those based on unnecessary or 
inappropriate medication use. Polypharmacy has been associated with increased risk of disability 
and functional limitations that impair a person's ability to live independently. Older adults are a 
population of interest as they are at increased risk for both polypharmacy and functional 
impairments. Understanding the relationship between polypharmacy and functional impairment 
  
 
 
in older adults could help health care providers and policy makers to target an at-risk population 
for interventions. 
 
Objectives: 
1) To assess the relationship between the number of medications taken and functional status 
in community-dwelling older adults using a nationally representative dataset. 
2) To assess the change in the relationship between the number of medications taken and 
functional status over time (2 years and 4 years). 
3) To study confounders of the relationship between polypharmacy and functional status.  
Methods: Data came from the Health and Retirement Study (HRS), collected in the following 
years: 2004, 2006 and 2008. The primary outcome was functional limitation as measured using 
the following validated tools: activities of daily living and instrumental activities of daily living 
(ADL and IADL). The exposure under study was polypharmacy status (no polypharmacy: <5 
prescribed medications, and polypharmacy: ≥5 prescribed medications). Both cross-sectional and 
longitudinal models were used to examine different aspects of the relationship between 
polypharmacy and functional status. 
Results: A total sample size of 1,545 was included in our study. The prevalence of 
polypharmacy was 35.9% at the beginning of the study. Polypharmacy status was significantly 
associated with functional decline in both the cross-sectional and longitudinal analyses after 
controlling for confounders. Self-reported health (SRH) and light exercise were associated with 
functional decline in all cross-sectional analyses. Age, arthritis, and SRH were also associated 
  
 
 
with functional decline in all longitudinal analyses. Other confounders were also associated with 
functional decline.  
Conclusion: Polypharmacy, defined as the use of more than five prescribed medications is a 
significant risk factor for functional decline in community-dwelling older adults.
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Chapter 1 Introduction 
 
Aging is commonly associated with an increase in chronic conditions and medication 
usage. More than 62% of adults aged 65-74 years old experience multiple chronic diseases 
(Jokanovic et al. 2015). More than 81.5% of older adults aged 85 years and older have multiple 
chronic diseases such as diabetes, hypertension, arthritis, heart diseases, and cancer (Jokanovic et 
al. 2015; Quiñones et al. 2016). As chronic conditions increase with aging, medication usage also 
increases. One of the main concerns that occurs with medication usage is polypharmacy.   
 1.1 Polypharmacy definition 
Polypharmacy has no consensus definition in the literature. The definition varies, and 
there are two main ways to define polypharmacy. The first way depends on the number of 
medications taken, with commonly-used cutoffs defining polypharmacy as the use of five or 
more medications, excessive polypharmacy as the use of ten or more medications, and oligo-
pharmacy as the use of less than five medications (Gnjidic et al. 2012; Jyrkkä et al. 2011a). The 
numeric definition is considered to be simple and is used often in practice settings. The second 
definition considers unnecessary or potentially inappropriate use of medications (PIM), including 
duplication of medications, inappropriate dosing, under-prescribing, adverse drug reactions, 
drug-drug or drug-disease interactions, unnecessary medications, or (for older adults) the use of 
medications on the Beer’s list, which is a list of medications where the risks generally outweigh 
the benefits for most older adults (Fulton et al. 2005; Turner et al. 2015). Some definitions 
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consider only the number of prescribed medications, while others include over-the-counter 
(OTC) medications. The most common meaning of polypharmacy is the use of multiple 
medications. Multiple medications do not always have to be problematic ( Levy 2017). It is 
sometimes appropriate with no need for modification. Some older adults are on multiple 
medications and they are healthy, while others would be better off if their medications were 
fewer ( Levy 2017).  
I will be using the number of prescription medications that are taken on a regular basis 
(every day, every week, etc.) in the last year by participants (excluding OTC, herbal, or 
nutritional supplement numbers) as a measure to assess drug burden. An advantage of using the 
number of medications is the simplicity of measuring polypharmacy by this method, which is 
why this approach is widely used in research and clinical settings. Also, it is a quick screening 
tool that does not need excessive effort, a complicated equation, or software to calculate in 
clinical practice. It is a quick screening tool that could be used to identify individuals in need of 
intervention, and should not increase burden on the healthcare system. The number of 
medications should ideally include prescribed medications, OTC, herbals, and nutritional 
supplements that are used regularly (Sharma et al. 2016). Unfortunately, use of as needed and 
nonprescription products may not be clearly documented in the patient’s medical record or in 
databases used for this research. 
There are other alternative measures of assessing drug burden and they mainly look for 
PIM. For example, the Beer’s list contains more than 110 PIM and 60 drug-diseases for older 
adults to avoid. Other examples are a screening tool for older people's prescriptions (STOPP) 
which contains 80 indicators for appropriate prescribing, and a screening tool to alert prescribers 
to right treatments (START) (Barry et al. 2007; Sharma et al. 2016). PIM is a good way to 
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measure drug burden and individually assess each patient’s needs. However, the disadvantage of 
PIM is that it has many different tools that are time consuming to administer, are not widely used 
in clinical settings, require training for healthcare providers, and need to be individualized for 
each patient. Since assessing PIM’s use requires individual assessment of each participant’s 
prescription list and health history, it can be difficult to implement in secondary datasets and 
electronic health records that may be missing some of the necessary information. However, 
PIM’s use is one of the consequences of polypharmacy that should be evaluated in future studies 
(Lau et al. 2011; Lau et al. 2010).  
 
1.2 Polypharmacy prevalence 
The trend of prescribed medication usage by US community-dwelling older adults has 
been increasing from 1988 to 2010. At least 90% of older adults are taking at least one 
prescribed medications. In the recent studies, the prevalence of older adults taking more than five 
medications is 36% to 39%. This percentage has tripled between 1988 to 2010 from 12.8% to 
39.0%. This means that 1 in 3 older adults age 65 or older take five or more prescription 
medications. When adding OTC and supplement usage, the prevalence of older adults age 65 or 
older taking five or more medications increases to 67% (Charlesworth et al. 2015; Levy 2017). 
Polypharmacy is also recognized as the most important risk factor for having PIM (Blanco-Reina 
et al. 2015; Redston et al. 2018). 42.6% community-dwelling older adults had at least one PIM 
(Davidoff et al. 2015). The prevalence of PIM in older adults living in long-term care range from 
21.3% to 63.0% using the 2003 Beers criteria (Redston et al. 2018). The prevalence of PIM in 
Europe is 22.6% for community-dwelling older adults (Tommelein et al. 2015). 
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1.3 Polypharmacy risk factors and clinical consequences 
 Several factors are known to be associated with increased likelihood of polypharmacy, 
including old age, sex, chronic diseases, multiple prescribers, cognitive impairment and 
cardiovascular conditions (Jokanovic et al. 2015). Older adults often experience these risk 
factors. Polypharmacy has been associated with many negative outcomes in older adults, 
including increased risk of falls, functional decline, frailty, disability, drug-related problems, and 
higher health costs (Maher et al. 2014). These negative outcomes are observed in older adults in 
part due to physiological changes associated with aging including decreased hepatic and renal 
function, changes in body composition, decline in baseline performance and decreased 
homeostatic reserve. These physiological changes can cause changes in drug pharmacokinetics 
(absorption, distribution, metabolism, and elimination), or pharmacodynamics (receptor and drug 
action on the body) often resulting in increased drug exposure and exaggerated drug response 
(Bushardt et al. 2008). 
 
1.4 Functional status  
Functional status, the ability to perform typical daily activities, is an important aspect of 
quality of life and independent living in older adults. Functional status reflects the health status 
and independency of people. It is measured in different ways, most often assessing ability to 
performing activities of daily living (ADL). The most commonly used measure of ADL is the 
basic activities of daily living ADL: toileting, bathing, dressing, walking across a room, getting 
in or out of bed, and eating as defined by Katz (Katz & Akpom 1976) . Another common 
measure is instrumental activities of daily living (IADL), which examines the ability to do more 
  
5 
 
complex activities such as administration of own medications, food preparation, shopping, using 
the telephone, and managing money. A third way of examining functional status is to assess 
mobility by asking about the ability of walking several blocks, walking one block, walking 
across the room, climbing several floors of stairs, and climbing one flight of stairs. Mobility is 
often one of the first areas to decline (Peron et al. 2011).  
 
1.5 Rate of functional impairment and need for caregiver help  
Physical impairment may impact a person’s ability to function independently. Some of the risk 
factors for functional decline are diabetes, hypertension , heart problems, disease burden, 
depression, sedentary lifestyle, weight problems, and vision impairment (Dunlop et al. 2005; 
Stuck et al. 1999). One study analyzed the 2011 National Health and Aging Trends Study 
(NHATS), a study supported by the National Institute of Aging that collects information on older 
adults in all of the following settings: community, residential care, and nursing home in the USA. 
It collects comprehensive information about participants’ needs and disability, and it reported 
that 61.5% of adults age 65 and older had no difficulties performing ADL, 19.6 % had difficulty, 
and 28.7% received help from another person with ADL. The study also looked at IADL and 
reported that 62.8% of adults age 65 and older had no difficulties doing IADL, 12.4% had  
difficulty, and 24.8% received help from another person with IADL (Freedman & Spillman 
2014( . Overall, 75% of older adults receiving help were community-dwelling, whereas 15% 
lived in assisted living and 10% lived in a nursing home setting (Schulz et al. 2016). 
Another study reported that 35.5% of community-dwelling older adults aged 65 years and 
older have disabilities including: vision, self-care, independent living, mobility, and cognition 
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disabilities. However, this study did not address the specific type of functional limitation or 
condition associated with disabilities (Courtney-Long et al. 2015). Acccording to the Disability 
Statistics Organization, 7.6 % of commumity-dwelling adults aged 65 to 74 in the USA reported 
an independent living disability in 2016, while 24.8%  of adults above 75 reported an 
independent living disability (K. Lisa Yang and Hock E. Tan 2018). 
 
1.6 Polypharmacy and functional status  
Polypharmacy may increase the risk of functional disability and impair a person’s ability 
to perform ADL thus threatening older adults’ independence. A narrative review examined five 
studies looking at the relationship between functional decline in older adults and suboptimal 
prescribing, which was defined as “underuse or overuse of medications or prescribing potentially 
inappropriate medications (PIM)” (Peron et al. 2011). All of the studies included in the review 
were longitudinal, and the majority were conducted in community-dwelling older adults. In the 
studies that examined some measure of PIM, two reported an association between PIM and 
functional decline, and one reported no association (Hanlon et al. 2002; Pugh et al. 2008; 
Corsonello et al. 2009). Several studies assessing the relationship between polypharmacy and 
functional status have been conducted since this narrative review.  One study used a longitudinal 
design to evaluate whether polypharmacy (5 or more prescribed drugs) was associated with 
functional decline among community-dwelling older adults with dementia, and assessed whether 
this association may be modified by PIM (defined as use of medications on the Beer’s list) (Lau 
et al. 2011). The results showed that participants with dementia and polypharmacy are more 
likely to have lower functional status in the following visit. PIM did not increase the associated 
risk, and drugs to avoid in the Beers’ list did not show association with functional decline (Lau et 
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al. 2011). Another study showed that drug interactions impair functional status as measured by 
gait speed (a measure of mobility) in community-dwelling older adults (Naples et al. 2016). 
Since it is not ethical nor feasible to do controlled trials on older adults and expose them to 
multiple medications experimentally, an observational study is the best choice for looking at 
polypharmacy in older humans. An experimental study using groups of young and old male mice 
given five commonly used medications (simvastatin, metoprolol, omeprazole, acetaminophen, 
and citalopram) for 2-4 weeks showed that polypharmacy impaired mobility, balance, and 
strength in older male mice. The study authors noted that the relationship between physiological 
changes in aging and body response to medications might influence the relationship between 
polypharmacy and functional decline (Huizer-Pajkos et al. 2016).  
Although existing literature supports the idea of an association between polypharmacy 
and functional status, many of the current studies suffer from limitations such as the use of small 
samples. Additionally, although some longitudinal studies exist, none have used a nationally-
representative sample. The objective of this study was to use longitudinal data to investigate 
whether polypharmacy (defined using the number of prescribed medications) increases the risk 
of functional impairment, using a large nationally-representative sample of older adults in the 
USA. 
1.7 Significance 
Prescribing in older adults is challenging, not only because of age-related physiological 
changes, but also due to the need to weigh the benefit against the potential for harm in patients 
with multimorbidity and polypharmacy (Holmes et al. 2006). One of the main goals in treating 
older adults is the preservation of independence. It is important to mention that functional 
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impairment could be reversed by rehabilitation and controlling for disability risk factors like 
polypharmacy and depression (Pamoukdjian et al. 2017; Lin et al. 2012). One study showed that 
de-prescribing showed a significant difference in ADL between the control and intervention 
groups (Wehling et al. 2016; Thillainadesan et al. 2018). Based on the current published 
literature, polypharmacy may be an important risk factor for functional decline, but further 
research is needed to evaluate the impact of polypharmacy and to understand what other risk 
factors play a role in functional impairment along with polypharmacy. Likewise, most of the 
previous studies control only for the number of chronic conditions and they do not look at the 
relationship between functional decline and each chronic condition. To help advance this area of 
research, I studied functional status as the primary outcome measure and assessed its association 
with polypharmacy. Functional status is one of the quick screening tools that can predict 
institutionalization and death (Saliba et al. 2000). This study provides a rigorous extension of 
existing literature using longitudinal data and a large nationally-representative sample. Further 
examination of the relationship between polypharmacy and functional status may lead to new 
information which could help health care providers and policy makers target at risk populations 
for interventions and help older adults maintain independence.  
1.8 Specific aims 
The hypothesis guiding this research is that there is an association between polypharmacy 
and functional status in community dwelling older adults. The specific aims are to: 
1.  To determine the prevalence of prescription medication usage and adverse effects among 
community-dwelling US older adults 
a) To determine the prevalence of prescription medication use and baseline 
characteristics among community-dwelling US older adults 
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b) To assess the access to prescription medications among US older adults including: 
access to pharmacies, source of prescription drug insurance, and costs covered by 
insurance 
c) To determine the prevalence of self-reported side effects and unwanted reactions, and 
to understand the consequence of these adverse drug reactions (e.g. stopping or 
cutting down mediations, visiting the doctor’s office, or admission to the hospital or 
the emergency room)  
2. To assess the cross-sectional relationship between polypharmacy and functional status 
using a large nationally-representative dataset 
a) To assess the relationship between polypharmacy status and functional status 
measured by ADL in community-dwelling older adults in 2004  
b) To assess the relationship between polypharmacy status and functional status 
measured by ADL in community-dwelling older adults in 2008  
c) To assess the relationship between polypharmacy status and functional status 
measured by IADL in community-dwelling older adults in 2004  
d) To assess the relationship between polypharmacy status and functional status 
measured by IADL in community-dwelling older adults in 2008  
 
3. To assess the longitudinal relationship between polypharmacy and functional status using 
a large nationally-representative dataset 
a) To assess the relationship between polypharmacy status and functional status in 
community-dwelling older adults over time (4 years) 
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b) To assess the relationship between polypharmacy at baseline and change in functional 
status over time (2 years)  
 
4. To identify potential confounders of the relationship between polypharmacy and 
functional status 
a) To assess the role of chronic conditions in the relationship between polypharmacy 
and functional status  
b) To identify potential confounders or modifiers of the relationship between 
polypharmacy and functional status 
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Chapter 2 Literature Review 
 
 
2.1 Literature Review 
This chapter is an examination of the literature on the relationship between polypharmacy 
and functional status. Both functional dependency and medication problems are major concerns 
among the older adult population. A decline in functional status may lead to an increase in health 
system utilization and mortality, and is a major cause of functional dependency and 
institutionalization (Fried & Guralnik 1997). Functional decline is usually a gradual process 
resulting from aging and chronic conditions, which eventually affect the patient’s physical 
abilities, although sometimes an acute event such as a stroke or a fracture could trigger a sudden 
functional decline. The prognosis of functional decline depends on many factors such as a 
patient’s age, gender, education, physical activity, cognitive status, and social support (Fried & 
Guralnik 1997). It is important to mention that functional decline can sometimes be slowed or 
reversed by rehabilitation and managing disability risk factors like polypharmacy (for example: 
de-prescribing) and depression (Lin et al. 2012; Wehling et al. 2016; Thillainadesan et al. 2018). 
Thus, if good care and early intervention were available, this may provide functional stability or 
delayed decline. Older adults utilize a high number of medications, both prescription and 
nonprescription. However, the consequences of multiple prescription medication use on 
community-dwelling older adults are not well studied (Magaziner et al. 1989; Lau et al. 2011).  
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Based on a systematic review of the literature, I examined seven published papers that 
discuss the relation between polypharmacy or PIM and functional status, The article were 
selected based on the following inclusion criteria: 
1-Observational cross-sectional and longitudinal studies  
2-Older adults included in the study  
3-Participants were community-dwelling  
4-Study published in the English language  
and the following exclusion criteria: 
1-Restricted to specific drug categories and their relationship to functional decline  
I used the following databases: PUBMED, CINAHL, and GOOGLE SCHOLAR. My 
search strategy combined multiple search terms and MeSH terms to cover articles including the 
following search terms: “functional status” OR “functional limitation” OR “functional decline” 
OR “activity of daily living” OR “mobility” AND “polypharmacy” OR “multiple medications” 
OR “Perception” OR “ADL” OR “IADL”, and filter: from 01/2011 to 01/2018, because there 
was a review article published in 2011 that reviewed literature published through December 
2010. I included the articles identified in this published literature review in my search.  My 
search resulted in 350 articles. I excluded 71 articles as not relevant to the topic based on the 
title, and I reviewed the abstracts of 279 articles. I excluded 242 articles because they did not 
meet my inclusion criteria, and fully reviewed 37 articles. Of those 37 articles, I excluded 29 
articles that did not address the association between polypharmacy or PIM with functional status. 
One additional article was excluded because it was conducted in a hospital setting, leaving seven 
papers for critical review. Four of the seven papers selected were previously gathered in a 
narrative review (Peron et al. 2011). 
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I will first review the papers assessing polypharmacy and its relationship to functional 
status (Table 2.1) followed by the papers discussing PIM and its relationship to functional status 
(Table 2.2). The first paper by Magaziner et al. (1989) examined the relationship between 
polypharmacy (number of prescribed medications) and OTC use in community-dwelling older 
women, and the change in cognition, activities of daily living, and instrumental activities of daily 
living. This study was a longitudinal study over one year. It looked at white women in the 
Baltimore area age 65 and older (N= 609). This study examined self-reported ADL and IADL of 
each participant, and controlled for age, education, and number and severity of chronic 
conditions. For the analysis, they used a regression model with the function status scores after 
one year as the outcome variable and number of prescribed medications at baseline as the 
predictor variable, while controlling for the baseline variables. This study found no association 
between the number of prescribed medications and change in cognitive function. The number of 
prescribed medications increased the risk of decline in ADL, IADL, and depression. The OTC 
medication use was associated with decline in ADL only (J. Magaziner et al. 1989). However, 
this study had a significant generalizability limitation because only white females from the 
Baltimore area were included. Also, they did not look at each chronic condition individually. 
Moreover, they excluded patients who died or who entered institutions during follow up and this 
may attenuate their observation. 
The second study looked at the association between polypharmacy (6-9 medications) and 
excessive polypharmacy (≥10 medications) with functional, nutritional, and cognitive status. 
This study was conducted in Finland with a total sample size of (N=294) community-dwelling 
older adults aged at least 75 years and followed for three years. Polypharmacy in this study 
included all medication taken regularly including OTC and vitamins. Functional status was 
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measured by IADL. They controlled for age, sociodemographics, self-reported health, and 
comorbidity as measured by the functional comorbidity index score. It was found that both 
polypharmacy and excessive polypharmacy were associated with a decline in IADL. Change in 
functional status over a three-year period cannot be predicted by polypharmacy. This study had a 
small sample size and their results cannot be widely generalized. However, despite the small 
sample size, the association was strong. Moreover, they did not control for each chronic 
condition individually (Jyrkkä et al. 2011a).  
 
The third study was performed to evaluate the relationship between polypharmacy (≥5 
prescribed medications) and functional decline among community-dwelling older adults with 
dementia. They also wanted to evaluate whether PIMs (high risk drugs as defined by the 2003 
Beers criteria) could modify this relationship. This study analyzed data from the National 
Alzheimer’s Coordinating Center (NACC), where community-dwelling adults with dementia 
aged 65 years and older (N=1,994) were included. Polypharmacy was defined as the use of ≥5 
prescribed medications and they excluded patients with no prescription medication. The 
functional status was measured by both ADL and IADL. They controlled for age, race, and 
number of comorbid conditions from this list: hypertension, diabetes, hypercholesterolemia, 
thyroid disease, urinary/bowel incontinence, heart disease, and cerebrovascular disease. They 
found that participants with dementia and polypharmacy are more likely to have lower functional 
status. PIMs did not modify this relationship (Lau et al. 2011). The limitation of this study was 
that they did not account for OTC medications. The dataset used in this study did not have 
random sampling and thus its results cannot be nationally representative. Moreover, they only 
  
15 
 
controlled for the number of chronic conditions and they did not look at the effect of each 
condition on the relationship individually. 
The aim of the fourth study was to evaluate the association between three types of 
potentially suboptimal prescribing of medications: 1) drugs-to-avoid in the 1997 Beer’s list, 2) 
drug-drug interactions, and 3)  polypharmacy defined as ≥ 5 medications (prescription and 
OTC), with a latent variable representing a timed performance measure of functional status, the 
short physical performance battery (SPPB). The SPPB can be used to measure functional status 
by evaluating a person’s ability to perform three tasks: a balance score, a timed 3-meter walk, 
and a repeated sitting to standing up from a chair. This study used the Hispanic Established 
Populations for Epidemiologic Studies of the Elderly (HEPESE) of Mexican-American 
community-dwelling older adults. They followed participants for seven years and the sample size 
was (N=1,682). They controlled for sociodemographic characteristics along with smoking, 
weight, self-reported health conditions, cognition status, and specific chronic conditions 
(diabetes, hypertension, cancer, arthritis, stroke, and cardiovascular conditions) recognized by 
the National Center for Health Statistics as the leading cause of mortality and disability in the 
US. This study concluded that only polypharmacy defined as ≥5 medications was associated with 
a change in SPPB. One of the strengths of this study was that it looked at the relationship 
between specific chronic conditions and functional status and it reported a relationship between 
diabetes, arthritis, and stroke with functional decline. However, this study is only generalizable 
among community-dwelling Mexican-American older adults. Also, their high dropout rate and 
death rate in this study population may attenuate the results (Pugh et al. 2008). 
The fifth study was a cross-sectional study, performed to identify factors associated with 
disability specially polypharmacy (≥5 medications) among community-dwelling older adults in 
  
16 
 
the Irish longitudinal study. They also wanted to identify other factors that could be associated 
with functional decline. The study participants were (N=3,499). Polypharmacy was defined as 
the use of ≥5 medications. The functional status was measured by ADL, IADL and combined 
ADL/IADL. They controlled for twenty-five possible confounders. They found that 
polypharmacy was the third strongest factor associated with decline in ADL and IADL/IADL, 
after age and pain. Polypharmacy was the sixth strongest factor associated with IADL decline. 
(Connolly et al. 2017). The limitations of this study were the use of self-reported questionnaire 
which could introduce source of bias. Also, the definition of polypharmacy was not clear and not 
well-defined. They also had lots of missing data. 
Table 2.1: Studies examining the relationship between polypharmacy and functional status  
Author & 
year 
Study 
population 
Design  Polypharmacy 
definition  
Functional 
status 
Measurement 
Results & 
conclusion  
Magaziner 
et al. 1989 
Community-
dwelling white 
women in the 
Baltimore area 
age 65 and older 
(N= 609) 
Longitudinal 
study over 
one year 
1-Number of 
prescribed 
medications taken 
in last month  
2-Number of 
OTC taken last 
month 
Self-reported 
ADL, 
IADL 
1-Decline in both 
ADL and IADL 
with prescription 
medication usage  
2-Decline in ADL 
only with OTC 
usage 
Jyrkkä et 
al. 2011 
Community-
dwelling older 
adults aged at 
least 75 years 
(N=294) 
Longitudinal 
study for 
three years 
1-Non-
polypharmacy   
 ≤ 5medications* 
2-Polypharmacy 
6-9 medications* 
3-Excessive 
polypharmacy 
≥10 medications* 
 
Self-reported 
IADL 
1-Polypharmacy 
and excessive 
polypharmacy 
were associated 
with a decline in 
IADL 
2- Change in 
functional status 
over a three-year 
period cannot be 
predicted by 
polypharmacy  
Lau et al. 
2011 
Community-
dwelling adults 
with dementia 
Longitudinal 
for 4 years  
1-Ppolypharmacy 
≥5 Rx 
2-PIMs (high risk 
drugs as defined 
Self-reported 
ADL and 
IADL (decline 
was defined as 
1-Polypharmacy 
was associated 
with functional 
decline  
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aged 65 years and 
older (N=1,994) 
by the 2003 Beers 
criteria) as a 
modifier for the 
relation 
any decline in 
ADL and/or 
IADL) 
2-Participants 
with dementia and 
polypharmacy had 
a lower functional 
status 
3-PIMs did not 
modify the 
relation  
Pugh et al. 
2008¥ 
Community-
dwelling 
Mexican-
American older 
adults aged 65 
years and older 
(N=1,682) 
Longitudinal 
study for 
seven years 
Polypharmacy 
defined as ≥5 
medications 
(prescription and 
OTC) 
The short 
physical 
performance 
battery 
(SPPB) 
1-Polypharmacy 
showed an 
association with 
functional decline  
 
Connolly 
et al. 
2017 
Community-
dwelling Irish 
longitudinal 
survey of ageing 
(N=3,499) 
Cross-
sectional 
Polypharmacy 
defined as ≥5 
medications 
ADL, IADL 
and 
ADL/IADL 
1-Polypharmacy 
was the third 
strongest factor 
associated with 
ADL and 
IADL/ADL 
decline, after age 
and pain 
2-Polypharmacy 
was the sixth 
strongest factor 
associated with 
IADL decline. 
Rx: prescription medication only, * All medications taken regularly (including prescribed, OTC, 
and vitamins) 
¥ This study assessed both polypharmacy and PIM  
 
Hanlon et al. (2002) discussed the relationship between PIMs and functional decline. The 
definition of PIM in this study was the use of drug-to-avoid in the1997 Beer’s list or dosage, 
duplication, duration, drug-drug, or drug-disease interaction with eight medications classes 
(digoxin, nonsteroidal anti-inflammatory medications, calcium channel blockers, antihistamines, 
angiotensin converting enzyme inhibitors, benzodiazepines, antipsychotics, and antidepressants). 
This study used the fourth wave of the Duke Established Populations for Epidemiologic Studies 
of the Elderly (EPESE) and included community-dwelling older adults in North Carolina. The 
sample size was (N=3,234) and the study was longitudinal for 3 years. This paper evaluated the 
decline in the ADL, IADL, and the abbreviated Rosow-Breslau scale, which measures the 
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person’s ability to do heavy physical work around the house. They found no association between 
the use of PIMs and mortality. There was an association between PIMs (drug-drug or drug-
disease interaction) and decline in ADL. This study had several limitations including self-
reported functional status measures and limited generalizability. Furthermore, the drugs-to-avoid 
were only measured by looking at the classes of medications, and not the individual medications, 
that the patient used. It is important for health care providers to note that even though a 
medication may be on the Beers, it might be appropriate for the patient’s needs  (Hanlon et al. 
2002).     
The last paper discussed the impact of PIMs (drug-drug and drug-disease interactions) on 
functional status. This four-year longitudinal study used data from the Health, Aging and Body 
Composition Study (Health ABC) and participants were community-dwelling older adults 
Medicare recipients living in Pittsburgh, Pennsylvania, and Memphis, Tennessee (N=2,402). 
Gait speed decline ≥0.1 m/s was used to measure functional status. They controlled for self-
reported health, hospitalization in the last year, number of prescribed medications, number of 
OTC medications, depression, self-reported coronary heart disease, peripheral artery disease, 
diabetes, osteoarthritis, osteoporosis, pulmonary disease, and stroke. Results showed that drug 
interactions may increase the likelihood of gait speed decline among older adults. 
Generalizability and selection bias are the primary limitations in this study (Naples et al. 2016).  
Table 2.2: Studies examining the relationship between PIMs and functional status  
Author 
& year 
Study 
population 
Design  PIMs definition  Functional 
status 
Measureme
nt  
Results & 
conclusion  
Hanlon 
et al. 
2002 
Community-
dwelling older 
adults aged 65 
years and older 
Longitudinal 
study over 
three years 
1-drugs-to-avoid in 
1997 Beer’s list 
2-dosage 
3-duplication 
Self-
reported 
ADL, 
IADL,  
1- Decline in ADL 
only with drug-
drug, or drug-
disease interaction  
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in North 
Carolina 
(N=3,234) 
4-duration 
5-drug-drug or drug-
disease interaction 
with 8 medications 
classes 
Rosow-
Breslau 
scale 
2- No association 
between the use of 
PIMs and 
mortality 
Naples 
et al. 
2016 
Community-
dwelling older 
adults aged 65 
and older 
(N=2,402). 
 
Longitudinal 
study over 
four years 
PIMs: drug-drug and 
drug-disease 
interactions 
Gait speed 
decline ≥0.1 
m/s 
Drug interactions 
may increase the 
likelihood of gait 
speed decline 
among older 
adults  
Pugh et 
al. 
2008¥ 
Community-
dwelling 
Mexican-
American 
older adults 
aged 65 years 
and older 
(N=1,682) 
Longitudinal 
study for 
seven years 
1-Drugs-to-avoid in 
1997 Beer’s list 
2-Drug-drug 
interactions  
The short 
physical 
performance 
battery 
(SPPB) 
Drug to avoid and 
drug-drug 
interaction showed 
no association 
with decline in 
SPPB  
¥ This study assessed both polypharmacy and PIM  
 
 2.2 Gaps in the literature 
 The literature is sparse, but it suggests that there is an association between polypharmacy 
and functional status, and that polypharmacy is one of the important risk factors not only for 
functional decline but also for PIM use (Lau et al. 2010). Polypharmacy’s relationship with 
functional status needs further study. There is not as much research done in this area (Jyrkkä et 
al. 2011; Peron et al. 2011). Limitations in the studies reviewed in this chapter lead to some gaps 
in the literature that need to be addressed. The generalizability of all the studies is limited, since 
none of them used nationally representative datasets. Some of the studies used all medications 
including prescription and nonprescription for the number of medications, while others studies 
used only prescribed medications. An inconsistent definition of polypharmacy may lead to 
conflicting results. Using self-reported measures of polypharmacy, functional status or 
confounding variables can introduce bias such as information bias, which occurs when there is 
an inaccurate measurement or misclassification of diseases or exposures. Information bias can be 
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introduced by: 1) the instruments used to measure the exposure or 2) the study participants, if a 
participant cannot remember the information needed accurately (recall bias), having missing 
data, or giving a socially desirable response or 3) investigators asking leading questions or 
lacking proper training.   
Moreover, the studies that used PIMs did not individualize the process for each patient’s 
need to check whether medications on the drugs-to-avoid list might be appropriate for that 
patient, and thus results may be inaccurate. Another limitation is that each study had different 
potential confounders that were adjusted for. Most of the studies controlled for the number of 
chronic conditions and only one study looked at each chronic condition individually. Since 
polypharmacy is associated with chronic conditions, then it is important to look not only at the 
number of chronic conditions but also at each chronic condition. Understanding the relationship 
between each chronic condition, polypharmacy and functional decline will enrich the literature 
and help us to better understand these relationships. In conclusion, polypharmacy, defined as the 
use of a certain number of medications, is an important risk factor for functional decline and 
increases the risk of PIMs, adverse drug reactions. Polypharmacy needs more attention and we 
need to look at the potential confounders of the relationship. In my study, I will use a nationally 
representative dataset to understand the relationship between polypharmacy and functional status 
among community-dwelling older adults in the US. I will also look at each chronic condition as a 
potential confounder to better understand the relationship between polypharmacy and functional 
decline.  
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Chapter 3 Methodology 
 
 In Chapter 3, the methodology employed to address the specific aims posed in Chapter 1 
will be discussed. Data source, study design, study population and study variables will be 
elaborated. This study was reviewed and approved as exempt by Virginia Commonwealth 
University Institutional Review Board (IRB) (ID:HM20011568). 
3.1 Data source 
The Health and Retirement Study (HRS) is a nationally representative health survey of 
older adults in the United States. HRS follows an open cohort of adults age 50 years or older in 
the United States, with repeat surveys and new additions to the cohort every two years. This is a 
uniquely rich, longitudinal data set for the community of scientific and policy researchers who 
study the health, economics, and demography of aging. The National Institute on Aging sponsors 
the HRS and the Institute for Social Research at the University of Michigan collects the data. 
The main HRS longitudinal survey is publicly available, and supplementary surveys with 
potentially sensitive data are available with an application for restricted use data. HRS data 
collection is conducted by an in-person interview (face-to-face) for a random half of the sample 
followed by a telephone interview for the next survey which takes place after two years. The 
next cycle goes back to the in-person interview and so on. A by-proxy interview is conducted if 
the person is unable to answer for himself or herself. Self-reported questionnaires are used for 
supplementary surveys.  
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3.2 Study design  
This study is a retrospective longitudinal study that follows the same cohort of people in 
HRS biannually from 2004-2009. The first aim was to determine the prevalence of prescription 
medication usage and common response to adverse effects among community-dwelling US older 
adults. Data used in this study were collected by HRS biannually in 2004, 2006, and 2008 which 
corresponds to waves seven, eight and nine, and the supplementary drug survey data collected in 
2005, 2007, 2009 which correspond to Prescription Drug Survey (PDS)05, PDS07, and the 
Health and Well-Being Study (HWB)09. The HRS data is publicly available. The supplementary 
drug survey was collected by mail, and a special request through the HRS website was made to 
obtain these datasets. 
3.3 Data merge  
All waves were merged and cleaned, and all long data (PDS05, PDS07, HWB09) were 
converted to wide data to merge them with wide HRS waves (7, 8, 9). HRS waves used in this 
study were cleaned and compiled by RAND Corporation. Common participant identifiers (PN, 
HHID) were used to merges the files together. All variables in PDS05, PDS07, and HWB09 
were given a prefix, except for PN and HHID, to be able to merge them without overlapping 
since some variables have common names. After that, cleaning the dataset and recoding the 
variables needed for this study was performed. Details regarding merged files and recoding are 
available in the Appendix (Tables A, B, and C). 
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3.4 Study population  
This study used data from HRS waves 7, 8 and 9, which were collected in 2004, 2006 and 
2008, and from the supplementary surveys: 2005 and 2007 PDS, and 2009 HWB. The 
supplementary surveys provide data about medications. The PDS includes a subsample of the 
participants in the HRS; it is composed of two surveys, one of which was done in 2005 and the 
other in 2007. It is considered a supplementary survey designed to capture the change in 
prescription medication utilization before the implementation of Medicare part D and afterward. 
This survey is intended to capture prescription medication use, coverage, and satisfaction. The 
HWB (2009) is a continuation of the PDS survey to track and capture changes in prescription 
drug utilization and registration in Medicare Part D. The HWB followed the same people in PDS 
plus an additional 22% random sample from HRS. 
This study included respondents who were: 
1- Adults aged 65 years and older  
2- Community-dwelling at baseline 
Respondents were excluded if they were: 
1- Missing data about their functional status, number of medications, or necessary model 
covariates. 
2- Not followed in waves 7, 8, and 9 
3- Living in a nursing home at baseline 
4- Interviewed by proxy at baseline 
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After merging all files, all participants who had medication information and functional status 
information totaled 2259 participants. Inclusion and exclusion criteria were applied: 
removing participants younger than 65 years at baseline (593 were deleted) => 1666,  
removing participants interviewed by proxy at baseline (105 were deleted) =>1561, 
removing participants living in nursing homes at baseline (3 were deleted) => 1558, and  
removing participants who were alive but did not respond (13 were deleted) => 1545, resulting 
in 1545 participants included in the analysis. 
3.5 Study variables 
3.5.1 Main exposure variable 
The primary exposure in this study was polypharmacy, defined as the number of 
prescribed medications used regularly. This is the most commonly used definition in the 
literature (Masnoon et al. 2017), facilitating comparison of our results with other published 
studies.  HRS participants were asked if they were taking prescribed medications last year and if 
yes, then how many prescribed medications do they take regularly? Evidence of polypharmacy 
was also identified in the PDS and HWB datasets. Polypharmacy was categorized as present or 
absent using a definition that is commonly used in other studies (Pugh et al. 2008; Jyrkkä et al. 
2011; Lau et al. 2011):  
1-non-polypharmacy: using <5 prescribed medications 
2-polypharmacy: using ≥5 prescribed medications  
In the sensitivity analysis, different cut-offs were assessed as well:  
1-non-polypharmacy: using <5 prescribed medications 
2-polypharmacy: using 5-9 prescribed medications  
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3-excessive polypharmacy: using 10 or more prescribed medications  
3.5.2 PDS and HWB variables: 
From the medication drug survey data, the following information about prescribed medications 
were merged, cleaned, and coded:  drug names, duration of medication use, side effects, response 
to side effects and unwanted drug reactions, and source of prescribed medications. Prescription 
medication coverage at baseline was categorized as: some by self and rest by insurance, small 
discounts, full price, pay nothing, and other. However, at the end of the study the categories were 
collapsed into having a prescription medication coverage (yes, no). 
3.5.3 Main outcome  
The outcome examined in this study was functional status, which was assessed with two 
widely used and well-validated measures: activities of daily living (ADL) and instrumental 
activities of daily living (IADL). ADL in this data set include five basic activities: bathing, 
dressing, walking across a room, getting in or out of bed, and eating. IADL include food 
preparation, shopping, medication administration, using the telephone and managing money. 
Counts were used to measure the number of activities in which participants experience 
impairments, with a possible range of 0-5 for ADL and 0-5 for IADL, with lower scores 
indicating better function and higher scores indicating greater disability (Germain et al. 2016). 
Each score was dichotomized into a yes/no variable to represent whether participants experience 
difficulty performing tasks in that category (score ≥1) and those able to function without 
difficulties (score=0). 
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3.5.4 HRS variables  
All the variables were cleaned, and the missing observations were recoded to (.) for 
analysis purposes. Demographics were age, gender, race, ethnicity, years of education, marital 
status, and number of residents living in the same house including participant and spouse. 
Household income/wealth, which is the sum of all income in a household, was re-categorized 
according to the four quartiles (low, mid-low, mid-high, and high). Other variables used were 
self-reported health, smoking, and alcohol drinking. Obesity was measured by the body mass 
index (BMI), which measures the body fat by calculating the ratio of weight to height. If BMI ≥ 
30 kg/m2, the participant was considered obese. The amount of monthly light physical exercise 
was also used in our study. For health insurance, participants were asked whether they are 
covered by any government health insurance program. Other variables were proxy interviewed 
participants, and institutionalized participants in a nursing home or a health care facility. (See 
Table 3.1). 
Table 3.1 HRS variables considered in the study  
The confounder   The category  
Age  65-74 years 
≥75years 
Gender  Male  
Female  
Race and ethnicity  Non-Hispanic white  
Non-Hispanic African American 
Others  
Hispanic   
Years of education  0-6 years 
7-12 years 
>13 years 
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Marital status  Married  
Divorced  
Widowed  
Never married 
Number of residents living in the same house 
including participant and spouse 
Alone  
Two persons  
More than two 
Household income (wealth)  Low quartile <$16.000 
Mid-low quartile $16,000-$29,999.9 
Mid-high quartile $30,000-$54,999.9 
High quartile ≥ $55,000 
Self-reported health Excellent 
Very good 
Good  
Fair 
Poor 
Smoking Current smoker 
Former smoker  
Never smoker  
Alcohol drinking  Yes 
No  
Obesity  Obese 
Not obese 
Light exercise  Every day 
More than once per week 
Once per week 
One to three times per month 
Never 
Governmental health insurance  Yes  
No  
Proxy interview  Yes  
No 
Institutionalization   Yes 
No 
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3.5.5 Health conditions  
The number of chronic conditions is a count variable for how many chronic conditions 
each participant has ever been told that he/she  had out of the eight following chronic conditions: 
1) high blood pressure or hypertension,  2) high blood sugar or diabetes, 3) heart diseases 
including heart attack, angina, coronary heart conditions, angina, or congestive heart failure, 4) 
cancer or malignancy of any kind except skin cancer, 5) stroke or transient ischemic attack, 6) 
chronic lung disease, chronic bronchitis or emphysema except asthma, 7) psychiatric problems, 
and 8) arthritis or rheumatism. Each of the chronic conditions were coded as yes/no. Depression 
was measured using the Center for Epidemiologic Studies Depression (CESD) scale score. This 
score is the sum of 1) the "negative" indicators which include a yes answer to the following: 
depression, felt sad, lonely, everything was an effort, restless sleep, and could not get going and 
2) the "positive" indictors which includes a no answer to the following: feeling happy, and 
enjoying life. A score of four or more was considered depression. For cognitive impairment, I 
used the total cognition score, which is the sum of the total word recall and mental status 
summary scores, resulting in a score range of 0-35. As in prior HRS studies, 10 or lower in 
cognitive scores was considered impairment.  
Three common terms will be used in the upcoming chapters:  
1) Baseline (2004): data collected in the beginning of the study and files used were HRS 
2004 and PDS 2005  
2) Midline (2006): data collected in the middle of the study and files used were HRS 2006 
and PDS 2007 
3) Endline (2008): data collected in the end of the study and files used were HRS 2008 and 
HWB 2009 
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3.6 Statistical analyses  
Aim 1:  To determine the prevalence of prescription medication usage and adverse 
effects among community-dwelling US older adults  
Descriptive statistics were reported for the study variables. For continuous variables (age, 
years of education, number of people in the same house, and total household income) normality 
was assessed to choose between parametric and non-parametric tests. Normality was assessed by 
looking at the histogram and the Q_Q plot. Moreover, Goodness-of-fit tests (Kolmogorov-
Smirnov, Cramer-von Mises, and Anderson-Darling) were also used to assess normality and p-
value <0.05 suggests non-normality. For categorical variables, PROC SURVEY was used to 
report unweighted N and PROC SURVEYFREQ procedure was used to report the weighted 
percent in each category.  
Aim 2: To assess the cross-sectional relationship between polypharmacy and functional 
status using a large nationally-representative dataset 
After re-coding baseline, midline, and endline characteristics, Chi-square was performed 
to report un-weighted N followed by PROC SURVEYFREQ to report weighted % and Rao-Scott 
Chi-Square test to report the p-value. These tests were done between each variable of interest and 
participants with or without ADL impairment at baseline. A bivariate analysis between each one 
of our study variables and the main outcomes (ADL and IADL) at both baseline and end line was 
done using PROC SURVEYLOGISTIC procedure, the unadjusted odds ratio (OR) along with 
the 95% CI and p-value were recorded. Logistic regression was chosen because the main 
outcome variables (ADL and IADL) were dichotomous. The variables that showed an 
association with the outcomes (ADL and IADL) were then tested by building a model and using 
the manual backward elimination method (p=0.1). In this method, the least significant variable 
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was dropped, except the main predictor, until all remaining variables had p-value of 0.1 or less. 
This method allows us to keep the important variables in the model even if it was not significant. 
A collinearity check was not performed because all variables were categorical. These regressions 
analyses were weighted by the HRS sampling weights and accounted for the complex sampling 
by using PROC SURVEYLOGISTIC and PROC SURVEYFREQ. The subsample groups in the 
PDS and HWB files were accounted for by using appropriate HRS sampling weights (An & 
Lu,2016). Interactions were added to the model for self-reported health and polypharmacy, and 
self-reported health and each of the eight chronic conditions, but none were significant.  
Aim 3: To assess the longitudinal relationship between polypharmacy and functional status 
using a large nationally-representative dataset and Aim 4: To identify potential 
confounders of the relationship between polypharmacy and functional status 
  For longitudinal models, the adjustment was performed for the baseline variables, and the 
backward elimination method was also used. Polypharmacy status was kept in the model even if 
it was not significant. Moreover, multiple interactions were added to the model, but none was 
significant. Model assumptions and diagnostics were checked by PROC LOGISTIC procedure 
and the LACKFIT option to perform a Hosmer and Lemeshow Goodness-of-Fit Test. A non-
significant p-value rules out a gross lack of fit. Influential points were also checked to detect any 
unusual observations. 
3.7 Missing data  
Dealing with missing data in SAS starts with cleaning the data: 
1) checking for missing data for each variable we want to use,  
2) re-coding the missing for answer like (refusal, no response, unknown, etc.), and  
3) rechecking if variables are coded correctly, and 
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4) making a new data set with the variables of interest to ensure that no unneeded 
variables were included, especially in a large data set like HRS, which may increase the amount 
of missing information. Listwise deletion or complete case analysis was used in our study. 
Listwise deletion is a convenient simple method and it is the most commonly used method in 
research. Because of the large sample size available in this study, listwise deletion can be used 
without substantial loss of statistical power (Dong & Peng 2013). Moreover, the missing data is 
acceptable when it is less than 10% of the sample, which is the case in our study (Dong & Peng 
2013). HRS is a large survey with no intervention, so drop out because of an intervention 
resulting in not at random (MNAR) missing data is unlikely.  The missing data in this study is 
most likely missing completely at random (MCAR) which means the missed information is not 
related to the study, or missing at random (MAR) which means that the missed information can 
be explained, and there is a pattern but the reason is not related to the primary dependent 
variable. 
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Chapter 4 Results  
 
Aim 1: Descriptive results   
A total of 1558 HRS participants met our inclusion and exclusion criteria in 2004 and 
were followed up until 2008. However, 13 of these participants were lost to follow up but were 
still alive at the end of the study period so they were excluded, leaving 1545 participants in our 
study. Table 4.1 shows the baseline and endline characteristics of the study participants. 
Regarding our main study predictor polypharmacy, 64.1 % were taking less than five prescribed 
medications, and 35.9% were considered having polypharmacy and taking five or more 
prescribed medications at baseline. For self-reported health, we have quite good perceived 
health, as most reported very good to good health status. Regarding our primary outcome, ADL 
and IADL, 11.5% and 9.5% reported difficulties in those two outcomes at baseline. Also, the 
most common chronic health conditions were hypertension (55.7%) and arthritis (60.4%). 
Looking at the same participants after four years, 19.4% have shifted their age category from 64-
74 years to 75+ years. For polypharmacy, the percentage of individuals taking less than five 
prescribed medications decreased and the percentage meeting the criteria for polypharmacy 
increased over 4 years, indicating that drug burden increased over time in these participants. 
Participants reported difficulties in ADL (16.2%) and IADL (13.8%) at the endline, indicating a 
decline in functional status over time in this population. The percentage of individuals suffering 
from hypertension and arthritis also increased over time. 
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Table 4.1: Baseline and endline characteristics of the study population 2004 -2008 
 
Variables  2004 
Unweighted n  
(weighted %) 
2008 
Unweighted n  
(weighted %) 
Age (years) 
    65-74 
    ≥75 
 
1159 (70.8%) 
386 (29.2%) 
 
844 (51.4%) 
701(48.6%) 
Gender  
    Male  
    Female  
 
628 (41.0%) 
917 (59.0%) 
 
628 (40.8%) 
917 (59.2%) 
Race and Ethnicity 
    Non-Hispanic white  
    Non-Hispanic African American 
    Others  
    Hispanic   
 
1219 (86.2%) 
189 (6.8%) 
26 (1.9%) 
111 (5.1%) 
 
1205 (86.1%) 
186 (6.5%) 
26 (1.9%) 
109 (5.4%) 
Marital status  
    Married  
    Divorced  
    Widowed  
    Never married 
 
984 (63.8%) 
137 (7.9%) 
389 (25.9%) 
35 (2.4%) 
 
884 (56.2%) 
137 (7.9%) 
490 (33.5%) 
34 (2.4%) 
Polypharmacy  
    0-4 medications 
    ≥5 medications 
 
986 (64.1%) 
559 (35.9%) 
 
897 (59.3%) 
647 (40.7%) 
ADL  
    No difficulty  
    Difficulty  
 
1366 (88.5%) 
179 (11.5%) 
 
1284 (83.8%) 
261 (16.2%) 
IADL 
    No difficulty  
    Difficulty 
 
1403 (90.9%) 
142 (9.1%) 
 
1326 (86.2%) 
219 (13.8%) 
Self-reported health  
    Excellent 
    Very good 
    Good 
    Fair 
    Poor  
 
168 (10.7%) 
476 (32.1%) 
524 (34.7%) 
290 (17.6%) 
86 (4.8%) 
 
115 (7.4%) 
460 (31.7%) 
540 (35.8%) 
316 (18.4%) 
114 (6.7%) 
# of chronic condition  
    0 
    1 
    2 
    3 
    4 
    5 
    6 
    7 
 
182 (12.4%) 
409 (27.0%) 
456 (29.7%) 
313 (19.5%) 
129 (7.9%) 
39 (2.4%) 
15 (1.0%) 
2 (0.1%) 
 
105 (7.3%) 
300 (20.1%) 
463 (30.1%) 
367 (24.3%) 
184 (11.2%) 
81 (4.1%) 
29 (1.8%) 
7 (0.4%) 
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Hypertension 
    No 
    yes 
 
662 (44.3%) 
881 (55.7%) 
 
b521 (35.9%) 
1021 (64.1%) 
Diabetes  
    No 
    Yes  
 
1281 (84.3%) 
261 (15.7%) 
 
a1217 (80.1%) 
326 (19.9%) 
Heart conditions  
    No 
    Yes  
 
1168 (75.8%) 
377 (24.2%) 
 
1063 (69.5%) 
482 (30.5%) 
Lung conditions  
    No 
    Yes  
 
1433 (93.2%) 
111 (6.8%) 
 
a1367 (89.4%) 
167 (10.6%) 
Cancer  
    No 
    Yes  
 
1291 (83.2%) 
246 (16.8%) 
 
c1224 (79.3%) 
311 (20.7%) 
Stroke 
    No  
    Yes  
 
1143 (93.5%) 
102 (6.5%) 
 
b1377 (89.1%) 
165 (10.9%) 
Psychiatric conditions  
    No 
    Yes  
 
1396 (90.8%) 
148 (9.2%) 
 
a1350 (88.1%) 
191 (11.9%) 
Arthritis  
    No 
    Yes  
 
595 (39.6%) 
949 (60.4%) 
 
a488 (32.6%) 
1055 (67.4%) 
Total sample size N= 1545, a= 2 missing, b= 3 missing, c= 10 missing, PROC SURVEY 
was used for this analysis. 
 
Aim 1-A) To determine the prevalence of prescribed medication usage among community-
dwelling US older adults 
In our study, 9.8% did not take any prescribed medications, 54.3 % were taking 1-4 
prescribed medications, and 35.9% were taking five or more prescribed medications at baseline. 
The most commonly prescribed medications at baseline are presented in Table 4.2. Atorvastatin 
was the most commonly used prescribed medication in our study population in 2004. 
Atorvastatin is an HMG CoA reductase inhibitor, which helps lower blood cholesterol levels, and 
it helps reduce the risk of cardiovascular events. The second most common medication was 
levothyroxine, used to treat hypothyroidism. Metoprolol was the third most commonly used 
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medication. It is a beta-blocker used to control hypertension, manage patients after myocardial 
infarction, and to treat heart failure, tachycardia, and angina. 
Table 4.2: The most commonly prescribed medications at baseline  
Drug name  
 
N (%)  Pharmacological category   
Atorvastatin  
 
234 (15.1%) HMG CoA reductase inhibitor (lowers cholesterol) 
Levothyroxine  
 
213 (13.8%) Synthetic thyroxine to treat hypothyroidism 
Metoprolol  
 
201 (13.0%) Beta-blocker for angina and hypertension  
Lisinopril  
 
183 (11.8%) ACE inhibitor for hypertension and heart failure  
Atenolol  
 
142 (9.2%) Beta-blocker for angina and hypertension  
Hydrochlorothiazide  
 
141 (9.1%) Diuretic for hypertension 
Furosemide  
 
130 (8.4%) Potent loop diuretic  
Simvastatin  
 
126 (8.2%) HMG CoA reductase inhibitor (lowers cholesterol) 
Amlodipine  124 (8.0%) Calcium channel blocker for angina and 
hypertension and kidney problems  
Metformin  124 (8.0%) Oral antidiabetic agent that helps control blood 
sugar levels 
Warfarin   
 
59 (3.8%) Oral anticoagulant 
 
 
 
Aim 1-B) To assess the access to prescribed medications among US older adults including 
pharmacies, prescription insurance and source of payment  
The most common source for filling prescriptions in this community-dwelling older adult 
population was drug store chains (29.2%), followed by mail order (21.7%) and independent 
pharmacies (21.5%). Only 6.3% used clinic and hospital pharmacies. Filling prescribed 
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medications over the internet was the least used method (1%) at the time that this data was 
collected. Table 4.3 displays the sources were prescribed medications were obtained by 
participants in the HRS. The participants were allowed to choose more than one source for filling 
their prescribed medications. In Table 4.4 we can see the source of the prescription insurance. 
36.7% had employment-based drug insurance. 19.4% and 14.7% had Medicare HMO and 
Medicaid prescription insurance. The payment sources for prescribed medications among HRS 
participants is presented in Figure 4.1.  
Table 4.3: The source for obtaining prescribed medications from most common to least 
common source   
Source of prescribed medications  Yes n (%)  No n (%)  
Drug store chain  410 (29.2%) 994 (70.8%) 
Mail order  305 (21.7%) 1099 (78.3%) 
Independent pharmacy  302 (21.5%) 1101 (78.5%) 
Supermarket  208 (14.8%) 1196 (85.2%) 
Department store chain  170 (12.1%) 1234 (87.9%) 
Others  136 (9.7%) 1268 (90.3%) 
Free samples  130 (9.3%) 1274 (90.7%) 
Veterans' Administration pharmacy 103 (7.3%) 1301 (92.7%) 
Clinics or hospital  89 (6.3%) 1315 (93.7%) 
Internet  12 (0.9%) 1392 (99.1%) 
Total n = 1404; missing =141 
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Table 4.4: The source of prescribed medications insurance   
Source of prescription insurance  Yes n (%)  No n (%)  
Employment insurance   411(36.7%) 708(63.3%) 
Medicare HMO 217(19.4%) 902(80.6%) 
Medicaid  165(14.7%) 954(85.3%) 
Purchase from insurance  94(8.4%) 1025(91.6%) 
Veterans' Administration pharmacy 92(8.2%) 1027(91.8%) 
State pharmacy assistance  49(4.4%) 1070(95.6%) 
Others   207 (18.5%) 912(81.5%) 
Total n =1119; missing = 426 
 
   
Figure 4.1: Prescription coverage and payment    
 
I pay some of 
the price and 
insurance pays 
the rest
55%
I get a small 
discount off
13%
I pay full price 
for all 
medications 
19%
I don't pay 
anything
8%
Others
5%
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Aim 1 -C) To determine the prevalence of self-reported side effects and unwanted 
reactions, and to understand the consequences of adverse drug reactions (e.g. stopping or 
cutting down mediations, visiting the doctor’s office, admission to the hospital or the 
emergency room)  
This analysis investigates self-reported side effects, adverse reactions, and other 
medication-related problems in community-dwelling US older adults. HRS participants were 
asked if they had any side effects, unwanted reactions, or other health problems from 
medications in past year. 1060 participants responded “no,” 246 responded “yes” and 239 did not 
respond. Participants were then asked additional questions about the most severe unwanted 
reactions and their responses are summarized in Table 4.5. 
Table 4.5: Self-reported side effects, unwanted reactions, and the action taken in response 
to this reaction 
Questions asked  Yes  No  
1-Cut down or stop taking the drug on your own a 106 98 
2-Talk to a doctor about this reaction b 206 20 
3-Visit a doctor's office or emergency room because of this reaction c 67 142 
4-Doctor cut down or stopped the medication because of this reaction d 171 54 
5-Take another medication or treatment to treat this reaction e 78 143 
6-Admitted to a hospital overnight because of this reaction f 25 192 
This table reports data for those who responded yes, a= 42 missing, b= 20 missing, c= 37 
missing, d= 21 missing, e= 25 missing, f= 29 missing  
 
In Table 4.5, we can see that participants called the doctor if they had a severe drug 
reaction. Their doctors may cut down the medication or stop it, but most of the participants did 
not need another medicine to treat the reaction or to be admitted to the hospital. 
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Aim 2-To assess the cross-sectional relationship between polypharmacy and functional 
status using a large nationally-representative dataset 
 2-A) Cross-sectional study looking at the association between ADL and polypharmacy at 
baseline (2004)  
In the contingency Table 4.6, demographic and functional status-related factors are 
grouped by ADL difficulty and no difficulty. There was a significant difference in participants 
with and without ADL difficulties in the following factors: polypharmacy, marital status, number 
of people living in the same home, education, total household income, self-reported health status, 
number of chronic conditions, hypertension, diabetes, heart conditions, stroke, arthritis, 
psychiatric conditions, depression, drinking alcohol, obesity, and light exercise. The non-
significant variables where: age, gender, race, having a lung condition, having cancer, smoking 
status, cognitive status, and having government health insurance. A detailed bivariate analysis 
was then conducted to examine the demographic and functional status-related factors, with each 
outcome (ADL and IADL) in both baseline and endline. 
 
Table 4.6: Demographic and functional status-related factors, grouped by ADL no 
difficulty and difficulty    
Variable  2004 P-value c  
ADL no difficulty  
n a (weighted %)b 
ADL difficulty  
n a (weighted %)b 
Age (years) 
    65-74  
  ≥75  
 
1035 (71.4%) 
331 (28.6%) 
 
124 (66.7%) 
55 (33.3%) 
0.2925 
Gender  
  Male  
  Female  
 
569 (41.9%) 
797 (58.1%) 
 
59 (34.2%) 
120 (65.8%) 
0.1009 
Race  
    White  
    African American 
    Others  
 
1166 (90.6%) 
158 (6.4%) 
42 (3.0%) 
 
142 (87.2%) 
32 (10.0%) 
5 (2.8%) 
0.1855 
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Marital status  
    Married  
    Divorced  
    Widowed  
    Never married  
 
897 (65.6%) 
115 (7.5%) 
323 (24.4%) 
31 (2.5%) 
 
87 (50.1%) 
22 (10.6%) 
66 (37.3%) 
4 (2.0%) 
0.0025 
Education  
    0-6 years  
    7-12 years  
    >13 years  
 
59 (3.2%) 
766 (55.5%) 
541 (41.2%) 
 
19 (8.2%) 
120 (67.5%) 
40 (24.2%) 
<0.0001 
# of people living in 
same house  
    Alone  
    2 persons  
    More than 2 
 
 
344 (27.1%) 
816 (58.3%) 
206 (14.6%) 
 
 
54 (32.8%) 
89 (46.3%) 
36 (20.9%) 
0.0300 
Wealth 
    Lowest quartile 
    Mid-low quartile 
    Mid-high quartile 
    Highest quartile 
 
283 (19.5%) 
322 (23.0%) 
382 (28.5%) 
379 (29.0%) 
 
82 (41.8%) 
45 (24.8%) 
30 (18.7%) 
22 (14.7%) 
<0.0001 
Polypharmacy  
    0-4 medications 
    ≥5 medications  
 
1211 (65.2%) 
689 (34.8%) 
 
187 (55.5%) 
146 (44.5%) 
0.0053 
 
Self-reported health  
    Excellent  
    Very good 
    Good  
    Fair 
    Poor  
 
164 (12.0%) 
461 (35.1%) 
473 (35.5%) 
223 (14.6%) 
44 (2.9%) 
 
4 (1.8%) 
15 (9.6%) 
51 (28.6%) 
67 (40.3%) 
 42 (19.8%) 
<0.0001 
 
# chronic conditions 
    0 
    1 
    2 
    3   
    4 
    5 
    6-7 
 
175 (13.6%) 
378 (28.3%) 
406 (29.7%) 
264 (18.4%) 
104 1(7.1%) 
26 (6.7%) 
13 (1.0%) 
 
7 (3.3%) 
31 (17.0%) 
50 (29.2%) 
49 (27.6%) 
25 (14.2%) 
13 (6.7%) 
4 (2.1%) 
<0.0001 
Hypertension 
  No  
  Yes  
 
604 (45.7%) 
760 (54.3%) 
 
58 (33.3%) 
121 (66.7%) 
0.0048 
 
Diabetes  
  No  
  Yes 
 
1155 (86.1%) 
208 (13.9%) 
 
126 (70.3%) 
53 (29.7%) 
0.0001 
 
Heart conditions  
  No 
  Yes  
 
 
1046 (76.7%) 
320 (23.3%) 
 
122 (69.1%) 
57 (30.9%) 
0.0401 
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Lung conditions  
  No 
  yes 
 
1269 (93.1%) 
96 (6.9%) 
 
164 (93.4%) 
15 (6.6%) 
0.9285 
 
Cancer 
  No 
  Yes  
 
1141 (83.3%) 
219 (16.7%) 
 
150 (82.1%) 
27 (17.9%) 
0.0855 
 
Stroke 
  No 
  Yes   
 
1284 (94.3%) 
82 (5.7%) 
 
159 (86.7%) 
20 (13.2%) 
0.0052 
Psychiatric conditions 
  No 
  Yes  
 
1252 (92.1%) 
113 (7.9%) 
 
144 (81.2%) 
35 (18.8%) 
<0.0001 
 
Arthritis  
  No  
  Yes  
 
555 (41.8%) 
810 (58.2%) 
 
40 (22.6%) 
139 (77.4%) 
0.0002 
 
Cognitive impairment   
  No  
  Yes  
 
1349 (99.0%) 
17 (1.0%) 
 
174 (97.8%) 
5 (2.2%) 
0.1018 
Depression 
  No 
  Yes  
 
1241 (91.4%) 
125 (8.6%) 
 
125 (74.1%) 
54 (25.9%) 
<0.0001 
Governmental health 
plan 
  No 
  Yes 
 
 
38 (2.5%) 
1326 (97.5%) 
 
 
3 (1.9%) 
3176 (98.1%) 
0.6633 
 
Smoker 
  Current  
  Former  
  Never   
 
124 (8.3%) 
597 (44.6%) 
632 (47.1%) 
 
17 (10.4%) 
83 (46.6%) 
79 (43.1%) 
0.6321 
 
Alcohol drinking  
  No  
  Yes 
 
1032 (47.2%) 
868 (52.8%) 
 
231 (63.8%) 
102 (36.2%) 
<0.0001 
Obesity 
  No  
  Yes  
 
1041 (78.5%) 
313 (21.5%) 
 
94 (56.9%) 
84 (43.1%) 
<0.0001 
 
Light exercise  
  Every day 
  >1 week 
  1 per week 
  1-3 per month 
  Never 
 
92 (6.4%) 
777 (58.6%) 
346 (24.2%) 
73 (5.3%) 
77 (5.5%) 
 
8 (4.3%) 
80 (43.7%) 
43 (24.6%) 
12 (5.3%) 
36 (22.2%) 
<0.0001 
 
a-unweighted n value; b-weighted column percent, PROC SURVEYFREQ to report weighted 
column % and, c-Rao-Scott Chi-Square test 
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Bivariate and multivariable analyses were performed to examine the association between 
ADL and IADL with covariates that showed significance or prior knowledge of their importance 
from the literature. Looking at the bivariate analysis between ADL and variables at baseline 
(2004) without adjusting for other variables yielded several observations. Participants who were 
taking five or more prescribed medications were 1.6 (95% CI = 1.181-2.213) times more likely 
to have difficulties in ADL than participants who were taking less than five prescribed 
medications. Also, females were 1.5 (95% CI = 1.044-2.019) times more likely to have 
difficulties in ADL than males. The odds of having difficulties in ADL for divorced, widowed, 
and never married participants were 2.0 (95% CI = 1.189-3.273), 2.1 (95% CI = 1.493-2.973), 
and 1.3 (95% CI = 0.459-3.856) respectively, compared to married couples. Participants with 7-
12 years of education were almost 50% (95% CI = 0.280-0.844) as likely to report difficulties in 
ADL and participants with 13 years or more of education were nearly 23% (95% CI = 0.125-
0.422) as likely to report problems in ADL than participants with 6 years or less of education. 
Participants who were living with at least one person were 70% (95% CI = 0.484-0.997) as likely 
to have difficulty with ADL than participants who lived alone. For wealth and total household 
income, participants who were in mid-low income, mid-high income, and highest income 
quartiles were 50% (95% CI = 0.324-0.717), 27% (95% CI = 0.174-0.423), and 20% (95% CI = 
0.122-0.329) as likely to report difficulties in ADL than participants in the lowest quartile. For 
self-reported health, those who reported good, fair, or poor health status were 4.4 (95% CI = 
1.572-12.417), 12.3 (95% CI = 4.403-34.40), and 39.1 (95% CI = 13.312-114.994) times more 
likely to have difficulties in ADL than those reporting excellent health status. The number of 
chronic conditions also increased the likelihood of having ADL difficulties. Having any of the 
following chronic conditions: hypertension, diabetes, heart conditions, stroke, arthritis, and 
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psychiatric conditions, would result in a higher likelihood of reporting challenges in ADL 
compared to those who do not have these conditions as presented in Table 4.7. Also, depressed 
participants were 4.3 (95% CI = 2.967-6.211) times more likely to report challenges with ADL 
than non-depressed participants. Those who drink alcohol were 50% (95% CI = 0.386-0.740) as 
likely to have difficulties in ADL than non-drinkers. Obese participants were almost 3.0 (95% CI 
= 2.158-4.094) times more likely to report problems with ADL than non-obese participants. 
Participants who never do light exercise were 5.4 (95% CI = 2.360-12.256) times more likely to 
develop difficulties in ADL than participants who do light exercise daily. (See Table 4.7) 
The association between ADL at baseline with age, race, ethnicity, having lung conditions, 
cancer, having cognition impairment, having government health insurance, having prescription 
drug coverage, and smoking were not significant. 
Table 4.7: Bivariate associations between participants’ study variables and ADL at the 
baseline (2004) 
 
Predictor variable Unadjusted 
OR 
95% CI  p-value  
Polypharmacy  1.617 1.181-2.213 0.0027* 
Age (ref=65-74 years) 1.387 0.987-1.950 0.0598 
Gender (ref=male) 1.452 1.044-2.019 0.0267* 
Race (ref=white) 
    African American 
    Others 
 
1.663 
0.978 
1.095-2.526 
0.381-2.511 
0.0566 
Ethnicity (ref=Hispanic)  1.644 0.977-2.767 0.0611 
Marital status (ref=married) 
    Divorced  
    Widowed 
    Never married     
 
 
1.972 
2.107 
1.330 
 
1.189-3.273 
1.493-2.973 
0.459-3.856 
0.0001* 
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Education (ref=0-6 years) 
    7-12 years 
    >13 years  
 
 
0.486 
0.230 
 
0.280-0.844 
0.125-0.422 
< 0.0001* 
# of people living in the home 
(ref=alone) 
    2 people 
    >2  
 
 
 
0.695 
1.114 
 
 
0.484-0.997 
0.706-1.756 
0.0345* 
Wealth (ref=lowest quartile) 
    Mid-low quartile 
    Mid-high quartile 
    Highest quartile  
 
 
0.482 
0.271 
0.200 
 
0.324-0.717 
0.174-0.423 
0.122-0.329 
< 0.0001* 
Self-reported health (ref=excellent) 
    Very good  
    Good 
    Fair 
    Poor 
 
 
1.334 
4.420 
12.316 
39.125 
 
0.436-4.076 
1.572-12.417 
4.403-34.40 
13.312-114.994 
< 0.0001* 
Number of chronic conditions 
(ref=0) 
    1 
    2 
    3 
    4 
    5 
    6-7  
 
 
 
2.050 
3.079 
4.640 
6.010 
12.500 
7.692 
 
 
0.886-4.747 
1.396-6.925 
2.055-10.479 
2.551-14.381 
4.567-34.216 
1.991-29.717  
< 0.0001* 
Hypertension a 1.658 1.191-2.308 0.0027* 
Diabetes a 2.336 1.641-3.325 < 0.0001* 
Heart conditions a 1.527 1.089-2.142 0.0142* 
Lung conditions a 1.209 0.685-2.134 0.5123 
Cancer a 0.938 0.607-1.448 0.7721 
Stroke a 1.970 1.176-3.299 0.0100* 
Psychiatric conditions a 2.693 1.776-4.085 < 0.0001* 
Arthritis a 2.381 1.648-3.440 < 0.0001* 
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Cognitive impairment a 2.280 0.831-6.258 0.1095 
Depression a 4.292 2.967-6.211 < 0.0001* 
Government health insurance a 1.681 0.514-5.504 0.3905 
Prescription drug coverage 
(ref=some by self and rest by 
insurance) 
    Discounts  
    Full price  
    Pay nothing  
    Other  
 
 
 
1.052 
0.661 
0.663 
1.126 
 
 
0.644-1.716 
0.405-1.078 
0.309-1.296 
0.518-2.449 
0.3373 
Smoking (ref=current) 
    Former  
    Never  
 
1.014 
0.912 
 
0.581-1.769 
0.522-1.593 
0.8088 
Alcohol drinking a 0.535 0.386-0.740 0.0002* 
Obesity (ref=non-obese) 2.972 2.158-4.094 < 0.0001* 
Light exercise (ref=every day) 
    >1 week 
    1 per week 
    1-3 per month 
    Never 
 
 
1.184 
1.429 
1.890 
5.378 
 
 
0.555-2.527 
0.649-3.164 
0.734-4.868 
2.360-12.256 
< 0.0001* 
Using Atorvastatin a 1.216 0.799-1.852 0.3613 
* p-value < 0.05, indicates significant relationship, a= reference group is No 
 
 
A multivariable logistic regression model was developed with the significant variables in 
the bivariate analysis and ADL. A backward elimination method (p=0.1) was used, and the least 
significant variables were removed one at a time until the model had only variables with a p-
value of 0.1 or less. Tables 4.8 and 4.9 display the variables remaining in the model. The results 
of the final model for this cross-sectional analysis showed that polypharmacy, light exercise, 
self-reported health, depression, and obesity were all significant predictors for reporting ADL 
difficulties at baseline. Arthritis and psychiatric condition were in the final model because their 
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p-value was < 0.1 but > 0.05 (p=0.0598 and p=0.0891). Participants with polypharmacy were 1.4 
(95% CI = 1.047-1.971) times more likely to report ADL difficulties than participants with non-
polypharmacy after controlling for other confounders. Participants reporting good, fair, or poor 
health status were 4.2 (95% CI = 1.199-14.399), 11.2 (95% CI = 3.336-37.507) and 18.6 (95% 
CI = 5.194-66.773) times more likely to have ADL difficulties than participants with excellent 
health status. Those who never exercise lightly are 2.9 (95% CI = 1.073-8.001) times more likely 
to report ADL difficulties than those who exercise daily controlling for other confounders. 
Depressed individuals were 1.8 (95% CI = 1.020-3.160) times more likely to report ADL 
difficulties. Moreover, obese persons were 1.9 (95% CI =1.303-2.782) times more likely to 
report ADL difficulties. The detailed results are presented in Tables 4.8 and 4.9. According to 
the Goodness-of-Fit Test (p=0.9793), there was no gross lack of fit in this model. 
 
 
Table 4.8: The predictor variables in the cross-sectional final model for ADL at baseline   
Variables    p-value  
Polypharmacy 0.0256 
Self-reported health  < 0.0001 
Light exercise  0.0170 
Arthritis  0.0598 
Depression  0.0428 
Obesity  0.0013 
Psychiatric conditions 0.0891 
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Table 4.9: The adjusted odds ratio of the predictor variables in the cross-sectional final 
model for ADL at baseline  
  
Variables  Adjusted OR                  95% CI 
Polypharmacy  1.437 1.047 1.971 
Self-reported health (ref=excellent)    
   Very Good  1.620 0.458 5.728 
    Good  4.154 1.199 14.399 
    Fair  11.186 3.336 37.507 
    Poor  18.623 5.194 66.773 
Light exercise (ref= everyday)    
    >1 per week 0.897 0.419 1.918 
    1 per week 0.898 0.370 2.179 
    1-3 per month 0.780 0.293 2.075 
    Never  2.930 1.073 8.001 
Arthritis (ref= no) 1.602 0.980 2.620 
Depression (ref= not depressed) 1.795 1.020 3.160 
Obesity (ref= non-obese) 1.903 1.303 2.782 
Psychiatric conditions (ref= no)  1.606 0.928 2.779 
Goodness-of-Fit Test p= 0.9793, N= 1529, 16 missing observations were 
deleted  
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Aim 2-B) Cross-sectional study looking at the association between ADL and polypharmacy 
at endline (2008)  
The bivariate analysis at endline (2008) between ADL and study variables without 
adjusting for them showed the following observation: Participants who were taking five or more 
prescription medications were 3.6 (95% CI = 2.723-4.803) times more likely to have difficulties 
in ADL than participants who were taking less than five prescription medications. Also, 
participants aged 75 years and older were 1.9 (95% CI = 1.426-2.445) times more likely to have 
difficulties in ADL than participants aged 65-74 years. The odds of having difficulties in ADL 
for widowed participants were 1.9 (95% CI = 1.470-2.594) compared to married couples, 
however, divorced and never married couples did not show a significant association. Participants 
with 7-12 years of education were almost 50% (95% CI = 0.302-0.838) as likely to report 
difficulties in ADL, and participants with 13 years or more of education were nearly 33% (95% 
CI = 0.195-0.571) as likely to report problems in ADL than participants with 6 years or less of 
education. For wealth and total household income, participants who were in the mid-low income, 
mid-high income, and highest income quartiles were 56% (95% CI = 0.412-0.831), 40% (95% CI 
= 0.275-0.569), and 26% (95% CI = 0.174-0.395) as likely to report difficulties in ADL than 
participants in the lowest household income quartile. For self-reported health, those who reported 
good, fair, or poor health status were 4.4 (95% CI = 1.345-14.299), 16.5 (95% CI = 5.123-
53.252), and 59.3 (95% CI = 17.753-198.238) times more likely to have difficulties in ADL than 
those with excellent health status. The number of chronic conditions also increases the likelihood 
of having ADL difficulties. Having one of the following chronic conditions: hypertension, 
diabetes, heart conditions, stroke, lung conditions, arthritis, and psychiatric conditions results in 
increased likelihood of reporting difficulties in ADL than those who do not have those conditions 
  
49 
 
as presented in Table 4.10. Participants with cognitive impairment were 7 (95% CI = 4.110-
11.933) times more likely to report ADL difficulties compared to participants with good 
cognitive status. Also, depressed participants were 4.8 (95% CI = 3.455 -6.742) times more 
likely to report problems than non-depressed individuals. Those who drink alcohol were 55% 
(95% CI = 0.413-0.725) as likely to have difficulties in ADL than non-drinkers. Obese 
participants were almost 1.9 (95% CI = 1.408-2.461) times more likely to report difficulties in 
ADL than non-obese participants. Participants who never do light exercise or who exercise only 
one to three time per month were 9.3 (95% CI = 5.304-16.323) and 3.3 (95% CI = 1.655 -6.427) 
times more likely to develop difficulties in ADL than the participants who do light exercise 
daily, while other categories of light exercise were not significant. Participants interviewed by 
proxy were 10.6 (95% CI = 4.888-22.865) times more likely to report ADL difficulties compared 
to participants who completed the interviews themselves.  
The association between ADL at endline with gender, race, ethnicity, number of people living in 
the same home with the participant, having cancer, having government health insurance, having 
prescription drug coverage, smoking, and using atorvastatin were not significant. (See Table 
4.10) 
Table 4.10: Bivariate associations between participants’ study variables and ADL at the 
endline (2008) 
Predictor variable Unadjusted OR 95% CI  p-value  
Polypharmacy  3.617 2.723-4.803 < 0.0001* 
Age (ref=65-74 years) 1.867 1.426-2.445 < 0.0001* 
Gender (ref=male) 1.290 0.979-1.701 0.0709 
Race (ref=white) 
    African American 
    Others 
 
1.468 
0.905 
1.011-2.131 
0.400-2.047 
0.1215 
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Ethnicity (ref=Hispanic)  1.088 0.658-1.800 0.7428 
Marital status (ref=married) 
    Divorced  
    Widowed 
    Never married     
 
 
1.088 
1.952 
1.364 
 
0.652-1.816 
1.470-2.594 
0.553-3.364 
< 0.0001* 
Education (ref=0-6 years) 
    7-12 years 
    >13 years 
 
 
0.503 
0.333 
 
0.302-0.838 
0.195-0.571 
0.0001* 
# of people living in the home (ref=alone) 
    2 people 
    >2  
 
 
0.795 
1.083 
 
0.582-1.084 
0.723-1.623 
0.1485 
Wealth (ref=lowest quartile) 
    Mid-low quartile 
    Mid-high quartile 
    Highest quartile  
 
 
0.585 
0.396 
0.262 
 
0.412-0.831 
0.275-0.569 
0.174-0.395 
< 0.0001* 
Self-reported health (ref=excellent) 
    Very good 
    Good 
    Fair  
    Poor 
 
 
2.976 
4.401 
16.517 
59.324 
 
0.898-9.862 
1.345-14.299 
5.123-53.252 
17.753-198.238 
< 0.0001* 
Number of chronic conditions (ref=0) 
    1 
    2 
    3 
    4  
    5 
    6 -7 
 
 
1.108 
2.124 
2.818 
5.224 
11.200 
22.909 
 
0.459-2.674 
0.942-4.788 
1.250 -6.354 
2.272-12.013 
4.631-27.089 
7.837-66.966 
<0.0001* 
Hypertension a 1.781 1.310-2.422 0.0002* 
Diabetes a 2.134 1.590-2.862 <0.0001* 
Heart conditions a 1.786 1.358-2.348 <0.0001* 
Lung conditions a 2.215 1.536-3.193 <0.0001* 
Cancer a 1.118 0.806-1.549 0.5040 
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Stroke a 3.343 2.354-4.748 <0.0001* 
Psychiatric conditions a  3.396 2.433-4.741 <0.0001* 
Arthritis a  3.266 2.265-4.711 <0.0001* 
Cognitive impairment a 7.003 4.110-11.933 < 0.0001* 
Depression a 4.826 3.455 -6.742 < 0.0001* 
Government health insurance a 2.145 0.500-9.203 0.3045 
Prescribed medication coverage a 1.118 0.444-2.813 0.8133 
Smoking (ref=current) 
    Former  
    Never  
 
 
1.034 
1.047 
 
0.609-1.757 
0.717-1.776 
0.9851 
Alcohol drinking (ref=no) 0.547 0.413-0.725 < 0.0001* 
Obesity (ref=non-obese) 1.861 1.408-2.461 < 0.0001* 
Light exercise (ref=every day) 
    >1 week 
    1 per week 
    1-3 per month 
    Never 
 
1.059 
1.617 
3.261 
9.305 
 
0.614-1.828 
0.922-2.837 
1.655 -6.427 
5.304-16.323 
< 0.0001* 
Using Atorvastatin a 1.202 0.836-1.728 0.3202 
Proxy interview a 10.571 4.888-22.865 < 0.0001* 
* p-value < 0.05, indicates significant relationship, a= reference group is No  
 
The 2008 cross-sectional analysis evaluated the association between ADL and the 
significant variables in the bivariate analysis. Table 4.11 displays the significant variables in the 
model. Polypharmacy, age, self-reported health, light exercise, arthritis, obesity, depression, and 
psychiatric conditions were all significant predictors of reporting ADL difficulties at endline. 
Participants with polypharmacy were 1.9 (95% CI = 1.240 3.009) times more likely to report 
ADL difficulties than those without polypharmacy after controlling for other confounders. The 
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adjusted OR of participants aged 75 years or older was 2.1(95% CI = 1.461-3.006) times higher 
than participants aged 65-74 years. Participants reporting good, fair, or poor health status were 
4.8 (95% CI = 1.002-22.647), 11.7 (95% CI = 2.477-55.392), and 28.2 (95% CI = 5.795-
137.210) times more likely to have ADL difficulties than participants with excellent health 
status. Those who never lightly exercise were 3.6 (95% CI = 1.771-7.497) times more likely to 
report ADL difficulties than those who exercise daily controlling for other confounders. 
Individuals with arthritis were 2.3 (95% CI =1.322-3.851) times more likely to report ADL 
difficulties after controlling for other confounders. Moreover, obese persons were 1.6 (95% CI = 
1.100-2.246) times more likely to report ADL difficulties than non-obese participants. Depressed 
individuals were 2.7 (95% CI = 1.711-4.203) times more likely to report ADL difficulties than 
participants who were not depressed. In addition, individuals with psychiatric conditions were 
1.9 (95% CI = 1.221-3.011) times more likely to experience ADL difficulties after controlling 
for other confounders. The results of this analysis are presented in Tables 4.11 and 4.12. The 
model had a Goodness-of-Fit Test p= 0.3367, which indicates no gross lack of fit.  
 
 
Table 4.11: The predictor variables in the cross-sectional final model for ADL at endline   
Variables  p-value 
Polypharmacy  0.0044 
Age  0.0001 
Self-reported health  < 0.0001 
Light exercise  0.0005 
Arthritis  0.0036 
Depression  < 0.0001 
Obesity  0.0140 
Psychiatric conditions 0.0056 
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Table 4.12: The adjusted odds ratio of the predictor variables in the cross-sectional final 
model for ADL at endline   
Predictor variables Adjusted OR                    95% CI 
Polypharmacy  1.932 1.240 3.009 
Age (ref=65-74 years) 2.096 1.461 3.006 
Self-reported health (ref=excellent)    
   Very Good  3.926 0.900 17.126 
    Good  4.764 1.002 22.647 
    Fair  11.707 2.477 55.329 
    Poor  28.198 5.795 137.210 
Light exercise (ref= everyday)    
    >1 per week 1.019 0.506 2.053 
    1 per week 1.208 0.596 2.448 
    1-3 per month 2.168 0.864 5.444 
    Never  3.644 1.771 7.497 
Arthritis  2.256 1.322 3.851 
Depression  2.682 1.711 4.203 
Obesity  1.572 1.100 2.246 
Psychiatric conditions  1.917 1.221 3.011 
Goodness-of-Fit Test p= 0.3367, N= 1502, and 43 missing observations were deleted 
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Aim 2-C) Cross-sectional study looking at the association between IADL and 
polypharmacy at endline (2004)  
For IADL, the bivariate analysis at baseline (2004) between IADL and study variables 
without controlling for confounders resulted in the following observation: Participants with 
polypharmacy did not show a significant association with IADL. Age showed a significant 
association with IADL; participants aged 75 and older were 1.6 (95% CI = 1.072-2.249) times 
more likely to have difficulties with IADL than participants aged 65-74 years. African 
Americans were 1.5 (95% CI = 1.320-3.158) times more likely to have trouble with IADL than 
white participants, while other races did not show a significant difference. Participants with 7-12 
years of education were almost 35% (95% CI = 0.198-0.608) as likely to report difficulties in 
IADL, and participants with 13 years or more of education were almost 19% (95% CI=0.104-
0.360) as likely to report difficulties in IADL than those with 6 years or less of education. 
Participants living with more than two persons in the same household were 56% (95% CI = 
0.359-0.861) as likely to report IADL difficulties than participants living alone. For wealth and 
total household income, participants who were in the mid-low income, mid-high income, and 
highest income quartiles were 50% (95% CI = 0.324-0.776), 30% (95% CI = 0.183-0.484) and 
19% (95% CI = 0.109-0.338) as likely to report difficulties in IADL than participants with low 
household income. In self-reported health status, those who reported fair or poor health status 
were 7.1 (95% CI = 2.785-18.217) and 25.8 (95% CI = 9.624-69.207) times more likely to have 
difficulties in IADL than those with excellent health status while good and very good health 
status were not significant. The number of chronic conditions also increased the likelihood of 
having IADL difficulties. Having one of the following chronic conditions: hypertension, 
diabetes, heart conditions, lung conditions, stroke, arthritis, and psychiatric conditions would 
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result in reporting difficulties in IADL more often than those who do not have those conditions 
as presented in Table 4.13. Participants with cognitive impairment were 3 (95% CI =1.082-
8.195) times more likely to report IADL difficulties compared to participants with good 
cognitive status. Also, depressed participants were 3.7 (95% CI = 2.487-5.556) times more likely 
to report problems with IADL than non-depressed individuals. Former and never smokers were 
57% (95% CI = 0.337-0.976) and 51% (95% CI = 0.297-0.867) as likely to report difficulties in 
IADL compared to current smokers. Those who drink alcohol were 44% (95% CI = 0.301-0.635) 
as likely to have difficulties in IADL than non-drinkers. Obese participants were almost 2 (95% 
C I = 1.385-2.849) times more likely to report IADL difficulties than non-obese participants. 
Participants who never do light exercise were 11.2 (95% CI = 3.826-32.880) times more likely to 
develop difficulties in IADL than participants who do light exercise daily while other categories 
in the light exercise were not significant.  
The association between IADL at baseline with gender, ethnicity, marital status, having cancer, 
having government health insurance, and having prescription drug coverage were not significant. 
(See Table 4.13) 
 
Table 4.13: Bivariate associations between participants’ study variables and IADL at the 
baseline (2004) 
Predictor variable Unadjusted 
OR 
95% CI  p-value  
Polypharmacy  1.284 0.904-1.824 0.1632 
Age (ref=65-74 years) 1.553 1.072-2.249 0.0198* 
Gender (ref=male) 0.930 0.655-1.319 0.6826 
Race (ref=white) 
  African American 
  Others  
 
 
1.468 
0.484 
 
1.320-3.158 
0.116-2.022 
0.0029* 
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Ethnicity (ref=Hispanic)  1.216 0.650-2.273 0.5402 
Marital status (ref=married) 
    Divorced  
    Widowed/Never married    
 
1.436 
1.225 
 
 
0.814-2.533 
0.832-1.805 
0.4341 
Education (ref=0-6years) 
    7-12 years 
    >13 years  
 
 
0.347 
0.193 
 
0.198-0.608 
0.104-0.360 
< 0.0001* 
# of people living in the home 
(ref=alone) 
    2 people 
    >2 
 
 
 
0.630 
0.556 
 
 
0.381-1.041 
0.359-0.861 
0.0307* 
Wealth (ref=lowest quartile) 
  Mid-low quartile 
  Mid-high quartile 
  Highest quartile   
 
 
0.502 
0.298 
0.192 
 
0.324-0.776 
0.183-0.484 
0.109-0.338 
< 0.0001* 
Self-reported health (ref=excellent) 
    Very good 
    Good 
    Fair  
    Poor 
 
 
1.430 
1.771 
7.123 
25.808 
 
0.528-3.872 
0.671-4.674 
2.785-18.217 
9.624-69.207 
< 0.0001* 
Number of chronic conditions (ref=0) 
    1 
    2 
    3 
    4 
    5 
    6 -7 
 
 
1.151 
2.014 
3.768 
5.140 
11.111 
21.875 
 
0.472-2.806 
0.876-4.630 
1.654 -8.588 
2.124-12.441 
4.021-30.703 
6.175--66.966 
< 0.0001* 
Hypertension a 1.802 1.240-2.618 0.0020* 
Diabetes a 2.138 1.442-3.169 0.0002* 
Heart conditions a 2.270 1.587-3.246 <0.0001* 
Lung conditions a  2.913 1.773-4.784 <0.0001* 
Cancer a 1.146 0.727-1.807 0.5579 
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Stroke a 3.032 1825-5.036 < 0.0001* 
Psychiatric conditions a 3.067 1.947-4.767 < 0.0001* 
Arthritis a 2.307 1.534-3.648 < 0.0001* 
Cognitive impairment a 2.978 1.082-8.195 0.0346* 
Depression a 3.717 2.487-5.556 < 0.0001* 
Government health insurance a 0.581 0.240-1.405 0.2282 
Prescription drug coverage  
    Discounts  
    Full price  
    Pay nothing  
    Other  
 
 
0.933 
0.783 
0.422 
1.013 
 
0.536-1.624 
0.472-1.299 
0.167-1.068 
0.421-2.436 
0.4174 
Smoking (ref=current) 
   Former  
   Never  
 
 
0.573 
0.508 
 
0.337-0.976 
0.297-0.867 
0.0044* 
Alcohol drinking (ref=no) 0.437 0.301-0.635 < 0.0001* 
Obesity a 1.987 1.385-2.849 0.0002* 
Light exercise (ref=every day) 
    >1 week 
    1 per week 
    1-3 per month 
    Never 
 
 
1.741 
2.673 
1.499 
11.217 
 
0.619-4.902 
0.932-7.665 
0.390-5.771 
3.826-32.880 
< 0.0001* 
Using Atorvastatin a 1.026  0.631-1.669 0.9173 
* p-value < 0.05 indicates a significant relationship 
The association between IADL in 2004 and the significant variables in the bivariate 
analysis was then evaluated using a multivariable model. Table 4.14 displays the significant 
variables in the model. Polypharmacy did not significant association after controlling for other 
confounders. Self-reported health, light exercise, having heart conditions, drinking alcohol and 
total household income were all significant predictors of reporting IADL difficulties at baseline. 
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Participants reporting poor health status were 5.7 (95% CI = 1.440-22.552) times more likely to 
have IADL difficulties than participants with excellent hath status. Those who never lightly 
exercise were 5 (95% CI = 1.442-17.205) times more likely to report IADL difficulties than 
those who exercise daily controlling for other confounders. Individuals with heart conditions 
were 1.8 (95% CI = 1.156-2.957) times more likely to report IADL difficulties after controlling 
for other confounders. For wealth and total household income, participants who were in the mid-
low income and highest income quartiles were 66% (95% CI = 0.438-0.989) and 36% (95% CI = 
0.170-0.764) as likely to report difficulties in IADL than participants in the low household 
income quartile. Results of the multivariable analysis are presented in Tables 4.14 and 4.15. The 
model had a Goodness-of-Fit Test p= 0.8325, which indicates no gross lack of fit. 
 
Table 4.14: The predictor variables in the cross-sectional final model for IADL at baseline   
Variable  p-value  
Polypharmacy  0.5080 
Self-reported health   <0.0001 
Light exercise  0.0010 
Heart condition  0.0114 
Psychiatric conditions  0.0629 
Alcohol drinking 0.0657 
Wealth  0.0342 
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Table 4.15: The adjusted odds ratio of the predictor variables cross-sectional final model 
for IADL at baseline   
Predictor variable  Adjusted OR 95%CI 
Polypharmacy   1.153 0.751 1.771 
Self-reported health (ref=excellent)    
 Very Good  0.991 0.279 3.525 
  Good  0.689 0.194 2.447 
  Fair  2.388 0.693 8.225 
  Poor  5.699 1.440 22.552 
Light exercise (ref= everyday)    
  >1 per week 1.195 0.387 3.694 
  1 per week 1.446 0.463 4.514 
  1-3 per month 0.753 0.160 3.542 
  Never  4.982 1.442 17.205 
Heart condition  1.849 1.156 2.957 
Psychiatric condition 1.561 0.975 2.500 
Alcohol drinking (ref=no) 0.700 0.479 1.024 
Wealth (ref=lowest quartile)    
   Mid-low quartile  0.658 0.438 0.989 
   Mid-high quartile  0.551 0.300 1.013 
   Highest quartile  0.360 0.170 0.764 
Goodness-of-Fit Test p= 0.8325, N= 1543 and 2 missing observations were deleted 
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Aim 2-D) Cross-sectional study evaluating the association between IADL and 
polypharmacy at endline (2008)  
The endline (2008) bivariate analysis to examine the association between IADL and 
covariates yielded the following results: participants with polypharmacy were 2.6 (95% CI = 
1.968-3.555) times more likely to report IADL difficulties than the group without polypharmacy. 
Age significantly associated with IADL difficulty, and participants aged 75 and older were1.8 
(95% CI = 1.354-2.416) times more likely to have difficulties in IADL than participants aged 65-
74 years. Females were 1.6 (95% CI = 1.195-2.205) times more likely to report IADL difficulties 
than males. The odds of having difficulties in IADL for widowed were 2.2 compared to married 
couples (95% CI = 1.604-2.965), however, divorced and never married couples did not show a 
significant association. Participants with 7-12 years of education were almost 60% (95% 
CI=0.349-0.692) as likely to report difficulties in IADL and participants with 13 years or more of 
education were almost 33% (95% CI = 0.184-0.595) as likely to report difficulties in IADL 
compared to participants with 0-6 years of education. Participants living with more than two 
persons in the same household were 41% (95% CI = 0.411-0.0.886) as likely to report IADL 
difficulties than participants living alone. Regarding wealth and total household income, 
participants who were mid-low income, mid-high income, and highest income quartiles were 
48% (95% CI = 0.327-0.692), 34% (95% CI = 0.229-0.498) and 20% (95% CI = 0.128-0.320) as 
likely to report difficulties in IADL than participants with low household income. For self-
reported health status, those who reported fair or poor health status were 5.6 (95% CI = 2.346-
13.156) and 17.5 (95% CI = 7.130-43.150) times more likely to experience difficulties in IADL 
than individuals with excellent health status, while good and very good health status were not 
significant. Having four or more chronic conditions increases the chances of reporting IADL 
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difficulties. Having one of the following chronic conditions: hypertension, diabetes, heart 
conditions, lung conditions, stroke, arthritis, and psychiatric conditions resulted in reporting 
difficulties in IADL than those who do not have those conditions as presented in Table 4.16. 
Participants with cognitive impairment were 10.3 (95% CI = 6.000-17.735) times more likely to 
have IADL difficulties compared to participants with good cognitive status. Depressed 
participants were 4.5 (95% CI = 3.184-6.437) times more likely to experience difficulty in IADL 
than non-depressed individuals. Alcohol drinkers were 47% (95% CI = 0.342-0.636). as likely to 
have difficulties in IADL than non-drinkers. Participants who never do light exercise or exercise 
only 1-3 times per month were 9.0 (95% CI = 4.988-16.092)  and 3.1 (95% CI = 1.513-6.306) 
times more likely to develop difficulties in IADL than the participants who do light exercise 
daily while other categories in the light exercise were not significant. Participants interviewed by 
proxy were 18.4 (95% CI = 8.080-41.896) times more likely to report ADL difficulties compared 
to participants who completed the interviews themselves. The association between IADL at 
baseline with race, ethnicity, having cancer, having government health insurance, having 
prescription drug coverage, smoking, and obesity were not significant.  
Table 4.16: Bivariate associations between participants’ characteristics and IADL at the 
endline (2008) 
Predictor variable Unadjusted 
OR 
95% CI  p-value  
Polypharmacy  2.645 1.968-3.555 < 0.0001* 
Age (ref=65-74 years) 1.809 1.354-2.416 < 0.0001* 
Gender (ref=male) 1.623 1.195-2.205 0.0019* 
Race (ref=white) 
  African American 
  Others  
 
 
1.443 
1.118 
 
0.968-2.152 
0.493-2.535 
0.1960 
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Ethnicity (ref=Hispanic)  0.865 0.485-1.545 0.6246 
Marital status (ref=married) 
    Divorced  
    Widowed 
    Never married    
 
 
1.627 
2.181 
1.134 
 
0.983-2.694 
1.604-2.965 
0.391-3.291 
< 0.0001* 
Education (ref=0-6years) 
    7-12 years 
    >13 years  
 
 
0.603 
0.331 
 
0.349-1.041 
0.184-0.595 
< 0.0001* 
# of people living in the home 
(ref=alone) 
    2 people 
    >2 
 
 
 
0.927 
0.603 
 
 
0.610-1.408 
0.411-0.886 
0.0068* 
Wealth (ref=lowest quartile) 
  Mid-low quartile 
  Mid-high quartile 
  Highest quartile   
 
 
0.476 
0.338 
0.203 
 
0.327-0.692 
0.229-0.498 
0.128-0.320 
< 0.0001* 
Self-reported health (ref=excellent) 
    Very good 
    Good 
    Fair  
    Poor 
 
 
1.496 
1.772 
5.555 
17.540 
 
0.614-3.648 
0.740-4.246 
2.346-13.156 
7.130-43.150 
< 0.0001* 
Number of chronic conditions (ref=0) 
    1 
    2 
    3 
    4 
    5 
    6 -7 
 
 
1.328 
1.848 
2.049 
3.644 
7.000 
17.231 
 
0.559-3.158 
0.816-4.187 
0.898 -4.673 
1.564-8.490 
2.860-17.135 
5.970-49.733 
< 0.0001* 
Hypertension a 1.483 1.076-2.044 0.0161* 
Diabetes a 1.460 1.053-2.026 0.0234* 
Heart conditions a 1.485 1.104-1.996 0.0089* 
Lung conditions a  1.879 1.263-2.796 0.0019* 
Cancer a 1.069 0.752-1.520 0.7108 
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Stroke a 3.574 2.484-5.141 < 0.0001* 
Psychiatric conditions a 3.851 2.726-5.440 < 0.0001* 
Arthritis a 2.213 1.547-3.166 < 0.0001* 
Cognitive impairment a 10.316 6.000-17.735 < 0.0001* 
Depression a 4.527 3.184-6.437 < 0.0001* 
Government health insurance a 0.778 0.262-2.308 0.6504 
Prescription drug coverage a 0.929 0.345-2.497 0.8833 
Smoking (ref=current) 
   Former  
   Never  
 
 
0.661 
0.801 
 
0.392-1.113 
0.479-1.341 
0.2150 
Alcohol drinking (ref=no) 0.466 0.342-0.636 < 0.0001* 
Obesity a 1.258 0.924-1.715 0.1453 
Light exercise (ref=every day) 
    >1 week 
    1 per week 
    1-3 per month 
    Never 
 
 
0.884 
1.395 
3.089 
8.959 
 
0.493-1.587 
0.765-2.544 
1.513-6.306 
4.988-16.092 
< 0.0001* 
Using Atorvastatin a 1.144 0.773-1.695 0.5012 
Proxy interview a 18.398 8.080-41.896 < 0.0001* 
* p-value < 0.05 indicates a significant relationship   
 
 
After adding the variables in the bivariate analyses into a multivariable model to examine 
their association with endline IADL, the following results were obtained: gender, age, 
polypharmacy, light exercise, self-reported health status, having a psychiatric condition, 
depression, and wealth were all significant predictors of reporting IADL difficulties in 2008. 
Participants with polypharmacy were 1.7 (95% CI = 1.080-2.525) times more likely to report 
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IADL difficulties than those without polypharmacy, after controlling for other confounders. 
Participants aged 75 years and older were1.7 (95% CI = 1.044-2.673) times more likely to have 
difficulties in IADL than participants aged 65-74 years, after controlling for other confounders. 
Females were 1.8 (95% CI = 1.128-2.777) times more likely to develop IADL difficulties than 
males, controlling for other confounders. Participants reporting poor health status were 5.4 (95% 
CI = 1.595-18.041) times more likely to have IADL difficulties than participants with excellent 
health status. Those who never lightly exercise were 5 (95% CI = 2.482-10.248) times more 
likely to report IADL difficulties than those who exercise daily, controlling for other 
confounders. Individuals with psychiatric conditions were 2.4 (95% CI = 1.407-4.015) times 
more likely to report IADL difficulties after controlling for other confounders. Depressed 
participants were 2.1 (95% CI = 1.268-3.534) times more likely to develop IADL difficulties 
than non-depressed individuals. For wealth and total household income, participants who were 
mid-high income and highest income quartiles were 50% (95% CI = 0.303-.819) and 47% (95% 
CI = 0.231-0.962) as likely to report difficulties in IADL than participants in the low household 
income quartile. The results of the analysis are reported in Tables 4.16 and 4.18. The Goodness-
of-Fit Test had a p= 0.8568, which indicate no gross lack of fit.  
Table 4.17 The predictor variables in the cross-sectional final model for IADL at endline 
Variable  p-value 
Polypharmacy 0.0216 
Age  0.0330 
Gender  0.0140 
Self-reported health  0.0005 
Light exercise  < 0.0001 
Psychiatric conditions  0.0017 
Depression  0.0049 
Wealth 0.0421 
 
  
65 
 
 
 
Table 4.18 The adjusted odd ratios of the predictor variables in the cross-sectional final 
model for IADL at endline 
Predictor variable Adjusted OR 95% CI 
Polypharmacy  1.651 1.080 2.525 
Gender (ref=male) 1.770 1.128 2.777 
Age (ref=65-74 years) 1.671 1.044 2.673 
Self-reported health (ref=excellent)    
    Very Good  1.281 0.401 4.093 
     Good  1.326 0.415 4.243 
     Fair  2.571 0.827 7.998 
     Poor  5.364 1.595 18.041 
Light exercise (ref= everyday)    
     >1 per week 0.749 0.380 1.475 
     1 per week 0.860 0.462 1.603 
     1-3 per month 2.165 0.892 5.254 
     Never  5.044 2.482 10.248 
Psychiatric conditions  2.376 1.407 4.015 
Depression  2.117 1.268 3.534 
Wealth (ref=lowest quartile)    
    Mid-low quartile  0.730 0.423 1.261 
    Mid-high quartile  0.498 0.303 0.819 
    Highest quartile  0.471 0.231 0.962 
Goodness-of-Fit Test p= 0.8568, N= 1508 and 37 missing observations were deleted 
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Aim 3 To assess the longitudinal relationship between polypharmacy and functional status 
using a large nationally-representative dataset 
Aim 3-A) To evaluate the relationship between polypharmacy status and functional status 
in community-dwelling older adults after 4 years  
Multiple models were developed to assess the relationship between polypharmacy status 
and functional status over time (4 years). The first longitudinal model adjusted for the baseline 
(2004) functional status-related variables and polypharmacy. The second model was the same 
with the addition of polypharmacy status at the endline (2008). These two models were assessed 
for the two outcomes, ADL and IADL. There were a total of four models (see Table 4.19). 
PROC SURVEYLOGISTIC was used to run the models.  
Table 4.19: Different models used to evaluate the relationship between polypharmacy 
status and functional status after 4 years 
Model 1 ADL at endline = Baseline functional-related variables + polypharmacy at 
baseline  
Model 2  ADL at endline = Baseline functional-related variables + polypharmacy at 
baseline + polypharmacy at endline 
Model 3 IADL at endline = Baseline functional-related variables + polypharmacy at 
baseline 
Model 4  IADL at endline = Baseline functional-related variables + polypharmacy at 
baseline + polypharmacy at endline 
All of the significant risk predictor variables examined previously in the cross-sectional 
model were added to the longitudinal model, and backward elimination was performed. 
Polypharmacy status was retained even if it was not significant. Table 4.19 displays the 
predictors evaluated in the model between ADL (2008), the baseline polypharmacy status 
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(2004), and the baseline (2004) function-related variables. Multiple interactions were added to 
the model between self-reported health and polypharmacy, self-reported health and each chronic 
condition, and each chronic condition and polypharmacy, but none was significant. Interactions 
were checked to make sure none had a modifying role in the relationship between polypharmacy 
and functional status. 
  In the first model, polypharmacy status at baseline was not a significant predictor of 
difficulties in ADL after 4 years. Taking ≥ 5 prescribed medications at the beginning of the study 
did not predict ADL difficulties at the end of the study. The important variables in the first model 
to assess developing ADL difficulties in 2008 were the following baseline (2004) variables: age, 
self-reported health status, arthritis, psychiatric conditions, obesity, and cognitive impairment. 
Participants aged 75 years and older were 2 (95% CI = 1.348-2.987) times more likely to have 
difficulties in ADL after 4 years than participants aged 65-74 years, controlling for confounders. 
Participants reporting good, fair, or poor health status were 3.2 (95% CI = 1.339-7.456), 8.4 
(95% CI = 3.577-19.581), and 17.5 (95% CI = 7.136-42.838) times more likely to have ADL 
difficulties than participants with excellent health status. Participants with arthritis were 2.1 
(95% CI = 1.381-3.306) times more likely to report ADL difficulties after 4 years than 
participants without arthritis. The odds of having ADL difficulties after 4 years was 1.9 (95% CI 
= 1.209-2.913) for those who have baseline psychiatric conditions, controlling for other 
confounders. Obese participants at baseline were 1.7 (95% CI = 1.141-2.643) times more likely 
to develop ADL difficulties after 4 years after adjusting for confounders. Participants with 
cognitive impairment at baseline were 4.1(95% CI = 1.255-13.630) times more likely to develop 
ADL difficulties after 4 years than participants with good cognition, after adjusting for 
confounders. See Table 4.20.  
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Table 4.20: Final model 1 for longitudinal analysis of ADL at endline and controlling for 
baseline functional-related variables and polypharmacy at baseline 
Baseline Predictor variable Adjusted OR 95% CI    p-value  
Polypharmacy 2004 1.115 0.850 1.463 0.4236 
Age (ref=65-74 years) 2.007 1.348 2.987 0.0009 
Self-reported health (ref=excellent)    < 0.0001 
   Very Good  1.609 0.733 3.534  
    Good  3.229 1.399 7.456  
    Fair  8.370 3.577 19.581  
    Poor  17.484 7.136 42.838  
Arthritis  2.136 1.381 3.306 0.0010 
Psychiatric conditions  1.876 1.209 2.913 0.0059 
Obesity  1.737 1.141 2.643 0.0110 
Cognitive impairment  4.135 1.255 13.630 0.0206 
Goodness-of-Fit Test p= 0.2894, N= 1529 and 16 missing observations were deleted 
 
 
Similar results to model 1 were obtained (Table 4.21) when adding polypharmacy status 
in 2008 to form model 2. This addition resulted in a significant effect for polypharmacy status in 
2008. Participants with polypharmacy in 2008 were 2.4 (95% CI = 1.666-3.570) times more 
likely to report ADL difficulties than participants without polypharmacy, adjusting for all other 
confounders. Polypharmacy status is important in the same year rather than 4 years earlier. 
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Table 4.21: Final model 2 for longitudinal analysis of ADL at endline and controlling for 
baseline functional-related variables and polypharmacy at both baseline and endline 
    
  In Table 4.22, IADL in 2008 could be predicted by the following baseline variables: age, 
self-reported health status, arthritis, stroke, depression, and alcohol drinking. Participants aged 
75 years and older were 2.7 (95% CI = 1.870-3.914) times more likely to have difficulties in 
IADL after 4 years than participants aged 65-74 years, controlling for confounders. Participants 
reporting fair or poor health status were 3.1 (95% CI = 1.232-7.656) or 6.1 (95% CI = 2.465-
15.079) times more likely to have IADL difficulties in 2008 than participants with excellent 
health status. Participants with arthritis were 1.7 (95% CI = 1.100-2.523) times more likely to 
report IADL difficulties after 4 years than participants without arthritis. The odds of having 
IADL difficulties after 4 years was 2.3 (95% CI = 1.393-3.905) for those who had baseline 
stroke history, controlling for other confounders. Depressed participants at baseline were 1.7 
(95% CI = 1049-2.760) times more likely to develop IADL difficulties after 4 years than non-
depressed participants, after adjusting for confounders. Participants who drink alcohol at baseline 
Baseline predictor variable Adjusted OR 95% CI  p-value  
Polypharmacy 2004 1.139 0.869 1.493 0.3389 
Polypharmacy 2008 2.439 1.666 3.570 < 0.0001 
Age (ref=65-74 years) 1.979 1.340 2.921 0.0009 
Self-reported health status (ref=excellent)    < 0.0001 
    Very Good  1.439 0.662 3.130  
    Good  2.624 1.152 5.979  
    Fair  6.246 2.710 14.394  
    Poor  12.191 4.958 29.975  
Arthritis  2.085 1.347 3.228 0.0014 
Psychiatric conditions  1.823 1.172 2.835 0.0087 
Obesity  1.566 1.014 2.419 0.0434 
Cognitive impairment  4.498 1.386 14.595 0.0133 
Goodness-of-Fit Test p= 0.8730, N= 1525 and 20 missing observations were deleted 
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were 54% (95% CI = 0.543-0.760) as likely to develop IADL difficulties after 4 years than 
participants who didn’t drink, after adjusting for confounders. Polypharmacy status at baseline 
was not a significant predictor for IADL difficulties. Taking ≥ 5 prescribed medications at the 
beginning of the study did not predict IADL difficulties at the end of the study. 
Table 4.22: Final model 3 for longitudinal analysis of IADL at endline and controlling for 
baseline functional-related variables and polypharmacy at baseline 
Baseline predictor variable Adjusted OR 95% CI  p-value  
Polypharmacy 2004 1.232 0.862 1.762 0.2468 
Age (ref=65-74 years) 2.705 1.870 3.914 < 0.0001 
Self-reported health status (ref=excellent)    < 0.0001 
   Very Good  1.174 0.465 2.966  
    Good  1.299 0.468 3.603  
    Fair  3.071 1.232 7.656  
    Poor  6.097 2.465 15.079  
Arthritis  1.666 1.100 2.523 0.0170 
Stroke  2.333 1.393 3.905 0.0018 
Depression  1.702 1.049 2.760 0.0318 
Alcohol drinking  0.543 0.387 0.760 0.0006 
Goodness-of-Fit Test p= 0.6880, N= 1543 and 2 missing observations were deleted 
 
A similar observation was seen when adding polypharmacy status in 2008 to form model 
4. This addition also resulted in a significant effect for polypharmacy status in 2008. Participants 
with polypharmacy in 2008 were 2.1 (95% CI = 1.460-2.872) times more likely to have IADL 
difficulties than participants without polypharmacy, adjusting for all other confounders. See 
Table 4.23. 
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Table 4.23: Final model 4 for longitudinal analysis of IADL at endline and controlling for 
baseline functional-related variables and polypharmacy at both baseline and endline 
Baseline predictor variable Adjusted OR 95% CI  p-value  
Polypharmacy 2004 1.264 0.890 1.797 0.1859 
Polypharmacy 2008 2.048 1.460 2.872 < 0.0001 
Age (ref=65-74 years) 2.721 1.871 3.959 < 0.0001 
Self-reported health (ref=excellent)    < 0.0001 
   Very Good  1.076 0.428 2.705  
    Good  1.094 0.403 2.968  
    Fair  2.420 0.985 5.944  
    Poor  4.541 1.864 11.062  
Arthritis  1.601 1.045 2.452 0.0312 
Stroke  2.046 1.232 3.398 0.0066 
Depression  1.629 0.993 2.671 0.0532 
Alcohol drinking  0.548 0.394 0.761 0.0742 
Goodness-of-Fit Test p= 0.5019, N= 1539 and 6 missing observations were deleted 
 
Aim 3-B) To assess the relationship between polypharmacy at midline and changes in 
functional status after 2 years  
For this specific aim, the relationship between functional status and polypharmacy was 
examined after 2 years, controlling for variables in 2006. Similar models to aim 3-A have been 
assessed and documented in Table 4.24. These four models were evaluated to better understand 
the relationship between polypharmacy and functional decline over time.  
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Table 4.24: Different models to evaluate the relationship between polypharmacy 
status and functional status after 2 years 
Model 5 ADL at endline = Midline functional-related variables + polypharmacy at 
midline  
Model 6  ADL at endline = Midline functional-related variables + polypharmacy at 
midline + polypharmacy at endline 
Model 7 IADL at endline = Midline functional-related variables + polypharmacy at 
midline 
Model 8  IADL at endline = Midline functional-related variables + polypharmacy at 
midline + polypharmacy at endline 
 
The important variables in the model 5 to predict developing ADL difficulties in 2008 
were the following midline (2006) variables: polypharmacy, age, self-reported health, light 
exercise, arthritis, psychiatric conditions, obesity, and cognitive impairment. Participants taking 
≥ 5 prescribed medications in 2006 were 1.8 (95% CI = 1.135-2.883) times more likely to 
develop ADL problems at the end of the study than participant taking < 5 prescribed 
medications. Participants aged 75 years and older were 1.7 (95% CI = 1.205-2.883) times more 
likely to have difficulties in ADL after 2 years than participants aged 65-74 years, controlling for 
confounders. Those who never lightly exercise were 2 times more likely to report ADL problems 
after 2 years than those who exercise daily controlling for other confounders. Participants 
reporting good, fair, or poor health status were 3.5 (95% CI =1.277-9.783), 5.4 (95% CI = 1.692-
17.144) and 12.0 (95% CI = 3.837-37.349) times more likely to have ADL difficulties after 2 
years than participants with excellent health status. Participants with arthritis were 2.5 (95% CI = 
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1.530-4.184) times more likely to report ADL difficulties after 2 years than participants without 
arthritis. The odds of having ADL difficulties after 2 years was 2.1 (95% CI = 1.177-3.870) for 
those who had psychiatric conditions, controlling for other confounders. Obese participants in 
2006 were 1.9 (95% CI = 1.174-2.998) times more likely to develop ADL difficulties after 2 
years, after adjusting for confounders. See Table 4.25 
Table 4.25: Final model 5 for longitudinal analysis of ADL at endline and controlling for 
midline functional-related variables and polypharmacy at midline 
Midline predictor variable Adjusted OR 95% CI  p-value  
Polypharmacy 2006 1.809 1.135 2.883 0.0138 
Age (ref=65-74 years) 1.728 1.205 2.478 0.0037 
Self-reported health status (ref=excellent)    < 0.0001 
   Very Good  1.747 0.565 5.406  
    Good  3.534 1.277 9.783  
    Fair  5.386 1.692 17.144  
    Poor  11.971 3.837 37.349  
Light exercise (ref= everyday)    0.0633 
    >1 per week 0.704 0.363 1.364  
    1 per week 0.804 0.470 1.377  
    13 per month 0.972 0.455 2.077  
    Never  2.027 0.897 4.582  
Arthritis  2.530 1.530 4.184 0.0005 
Psychiatric conditions 2.134 1.177 3.870 0.0135 
Obesity 1.873 1.174 2.988 0.0095 
Goodness-of-Fit Test p= 0.6893, N= 1289 and 256 missing observations were deleted  
 
In model 6, when adding polypharmacy status in 2008, the relationship between 
polypharmacy status in 2006 and ADL changed from significant to non-significant (p=0.5731). 
This addition also resulted in a significant effect for polypharmacy status in 2008 (p=0.0035). 
Participants with polypharmacy in 2008 were 2.2 (95% CI = 1.304-3.566) times more likely to 
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have ADL difficulties than participants without polypharmacy, adjusting for all other 
confounders (Table 4.26).  
Table 4.26: Final model 6 for longitudinal analysis of ADL at endline and controlling for 
midline functional-related variables and polypharmacy at both midline and endline 
Midline predictor variable Adjusted OR 95% CI  p-value  
Polypharmacy 2006 1.160 0.685 1.964 0.5731 
Polypharmacy 2008 2.156 1.304 3.566 0.0035 
Age (ref=65-74 years) 1.677 1.170 2.404 0.0057 
Self-reported health status (ref=excellent)    < 0.0001 
   Very Good  1.584 0.504 4.978  
    Good  3.156 1.121 8.882  
    Fair  4.732 1.487 15.057  
    Poor  9.861 3.164 30.736  
Light exercise (ref= everyday)    0.0405 
    >1 per week 0.688 0.357 1.328  
    1 per week 0.761 0.438 1.321  
    1-3 per month 0.914 0.428 1.953  
    Never  2.093 0.924 4.740  
Arthritis  2.564 1.546 4.252 0.0005 
Psychiatric conditions 2.086 1.137 3.829 0.0186 
Obesity 1.837 1.145 2.947 0.0127 
Goodness-of-Fit Test p= 0.4436, N= 1286 and 259 missing observations were deleted 
 
The relationship between IADL and polypharmacy after 2 years was also examined by 
similar methods used above. The important variables in model 7 to develop IADL difficulties in 
2008 while controlling for the midline (2006) variables were: age, self-reported health, light 
exercise, arthritis, psychiatric conditions, stroke, and wealth. Polypharmacy in this model was 
not significant, however the p-value was close to significant (p=0.0636). Participants aged 75 
years and older at midline were 2.3 (95% CI = 1.448-3.542) times more likely to have difficulties 
in IADL after 2 years than participants aged 65-74 years, controlling for confounders. 
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Participants reporting fair or poor health status were 3.4 (95% CI = 1.069-10.598) and 4.1 (95% 
CI = 1.061-16.058) times more likely to have IADL difficulties after 2 years than participants 
with excellent health status. Those who never lightly exercise were 3.6 (95% CI = 1.567-8.220) 
times more likely to report IADL problems after 2 years than those who exercise daily, 
controlling for other confounders. Participants with arthritis at midline were 1.9 (95% CI = 
1.049-3.264) times more likely to report IADL difficulties after 2 years than participants without 
arthritis. Participants with stroke history in 2006 were 2.1 (95% CI = 1.121-4.084) times more 
likely to have IADL difficulties after 2 years, after adjusting for confounders. 
The odds of having IADL difficulties after 2 years were 2.1 (95% CI = 1.230-3.471) for those 
who have psychiatric conditions, controlling for other confounders. Participants who were mid-
low, mid-high and highest income quartiles were 50% (95% CI = 0.285-0.880), 44% (95% CI = 
0.250-0.769), and 40% (95% CI = 0.174-0.914) as likely to report difficulties in IADL than 
participants in the low household income quartile. (See Table 4.27)  
 
Table 4.27: Final model 7 for longitudinal analysis of IADL at endline and controlling for 
midline functional-related variables and polypharmacy at midline 
Midline predictor variable Adjusted OR 95% CI  p-value  
Polypharmacy 2006 1.644 0.971 2.785 0.0636 
Age (ref=65-74 years) 2.265 1.448 3.542 0.0006 
Light exercise (ref= everyday)    <0.0001 
    >1 per week 0.687 0.377 1.252  
    1 per week 1.183 0.611 2.292  
    1-3 per month 1.180 0.427 3.263  
    Never  3.589 1.567 8.220  
Self-reported health status (ref=excellent)    0.0045 
   Very Good  1.409 0.476 4.171  
    Good  1.191 0.383 3.703  
    Fair  3.365 1.069 10.598  
    Poor  4.129 1.061 16.058  
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Midline predictor variable Adjusted OR 95% CI  p-value  
Arthritis  1.850 1.049 3.264 0.0342 
Stroke 2.140 1.121 4.084 0.0220 
Psychiatric conditions 2.066 1.230 3.471 0.0070 
Wealth (ref=lowest quartile)    0.0160 
    Mid-low quartile  0.501 0.285 0.880  
    Mid-high quartile  0.438 0.250 0.769  
    Highest quartile  0.399 0.174 0.914  
Goodness-of-Fit Test p= 0.8081, N= 1298 and 247 missing observations were deleted 
 
In model 8, adding polypharmacy status in 2008 to the model for the relationship 
between polypharmacy status in 2006 and IADL resulted in a significant effect for polypharmacy 
status in 2008 (p = 0.0199) while polypharmacy status in 2006 remained insignificant (p = 
0.6029). Participants with polypharmacy in 2008 were 1.8 (95% CI = 1.105-3.046).  times more 
likely to report IADL problems than participants without polypharmacy, adjusting for all other 
confounders, as seen in Table 4.28 
 
 
Table 4.28: Final model 8 for longitudinal analysis of IADL at endline and controlling for 
midline functional-related variables and polypharmacy at both midline and endline    
Midline predictor variable Adjusted OR 95% CI  p-value  
Polypharmacy 2006 1.177 0.630 2.197 0.6029 
Polypharmacy 2008 1.835 1.105 3.046 0.0199 
Age (ref=65-74 years) 2.212 1.420 3.446 0.0007 
Self-reported health status (ref=excellent)    0.0084 
   Very Good  1.279 0.422 3.874  
    Good  1.063 0.331 3.416  
    Fair  2.959 0.921 9.504  
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Midline predictor variable Adjusted OR 95% CI  p-value  
    Poor  3.248 1.056 9.990  
Light exercise (ref= everyday)    < 0.0001 
    > 1 per week 0.674 0.371 1.226  
    1 per week 1.139 0.587 2.208  
    1-3 per month 1.108 0.387 3.175  
    Never  3.715 1.614 8.549  
Arthritis  1.877 1.043 3.379 0.0362 
Stroke 2.091 1.114 3.924 0.0225 
Psychiatric conditions 2.003 1.184 3.389 0.0106 
Wealth (ref=lowest quartile)    0.0136 
    Mid-low quartile  0.486 0.277 0.853  
    Mid-high quartile  0.436 0.247 0.771  
    Highest quartile  0.383 0.167 0.877  
Goodness-of-Fit Test p= 0.6044, N= 1295 and 250 missing observations were deleted 
 
 Sensitivity analysis (1) 
In the following section, a sensitivity analysis was performed. The sensitivity analysis is 
a method used to determine how different values of the exposure change the impact on the 
outcome. Polypharmacy definition in this analysis was: 
1) non-polypharmacy: using <5 prescribed medications 
2) polypharmacy: using 5-9 prescribed medications  
3) excessive polypharmacy: using 10 or more prescribed medications 
At baseline, non-polypharmacy group had 986 (64.1%) participants, polypharmacy group had 470 
(30.4%) participants, and excessive polypharmacy had 89 (5.5%) participants. At endline, non-
polypharmacy group had 897 (59.1%) participants, polypharmacy group had 514 (32.6%) 
participants, and excessive polypharmacy had 130 (8.3%) participants. The sensitivity analysis 
was done to evaluate the relationship between polypharmacy status and functional status in 
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community-dwelling older adults after 4 years using different polypharmacy cut-offs. Similar 
approaches to previous analyses for building different models were conducted.  
Table 4.29: Different models to evaluate the relationship between polypharmacy status and 
functional status after 4 years using different polypharmacy cut-offs 
Model 9 ADL at endline = Baseline functional-related variables + polypharmacy and 
excessive polypharmacy at baseline  
Model 10  ADL at endline = Baseline functional-related variables + polypharmacy and 
excessive polypharmacy at baseline + polypharmacy and excessive 
polypharmacy at endline 
Model 11 IADL at endline = Baseline functional-related variables + polypharmacy and 
excessive polypharmacy at baseline 
Model 12 IADL at endline = Baseline functional-related variables + polypharmacy and 
excessive polypharmacy at baseline + polypharmacy and excessive 
polypharmacy at endline 
 
In model 9, polypharmacy at baseline was not a significant predictor of difficulties in 
ADL after 4 years as seen in model 1. Taking 5-9 prescribed medications at the beginning of the 
study did not predict ADL difficulties at the end of the study. Also, taking 10 or more prescribed 
medications at the beginning of the study did not predict ADL difficulties at the end of the study. 
The important variables in this model to assess developing ADL difficulties in 2008 were the 
same as model 1 except for obesity. Refer to Table 4.30.  
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Table 4.30: Final model 9 for longitudinal analysis of ADL at endline and controlling for 
baseline functional-related variables and polypharmacy and excessive polypharmacy at 
baseline 
Baseline Predictor variable Adjusted OR 95% CI    p-value  
Polypharmacy 2004 (ref= 0-4 Rx)      0.7136 
    Polypharmacy (5-9 Rx) 1.133 0.838 1.534  
    Excessive Polypharmacy (≥10 Rx) 0.980 0.467 2.055  
Age (ref=65-74 years) 1.853 1.312 2.617 0.0007 
Self-reported health (ref=excellent)    < 0.0001 
    Very Good  1.667 0.761 3.651  
     Good  3.417 1.492 7.823  
     Fair  9.161 3.961 21.185  
     Poor  20.368 8.283 50.083  
Arthritis  2.241 1.427 3.521 0.0007 
Psychiatric conditions  1.848 1.186 2.878 0.0076 
Cognitive impairment  3.788 1.183 12.127 0.0257 
Goodness-of-Fit Test p= 0.5127, N= 1543 and 3 missing observations were deleted, 
Rx=prescription medications  
 
A similar observation was noted when adding polypharmacy and excessive 
polypharmacy in 2008 to model 10 (Table 4.31). This addition resulted in a significant effect for 
polypharmacy and excessive polypharmacy in 2008. Participants with polypharmacy in 2008 
were 2.6 (95% CI = 1.663-3.909) times more likely to have ADL difficulties than participants 
without polypharmacy, adjusting for all other confounders. Participants with excessive 
polypharmacy at endline were 4.7 (95% CI = 2.704-8.096) times more likely to have ADL 
difficulties than participants without excessive polypharmacy, adjusting for all other 
confounders. Model 10 was similar to model 2.  
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Table 4.31: Final model 10 for longitudinal analysis of ADL at endline and controlling for 
baseline functional-related variables and polypharmacy and excessive polypharmacy at 
baseline and at endline 
 
 In model 11 and 12, similar observations were also noted. Polypharmacy and excessive 
polypharmacy at baseline were not significant predictors for IADL difficulties with p=0.461 
(Table 4.32). While when adding them at endline, they became significant as seen in Table 4.33. 
Participants with excessive polypharmacy at endline were 3.7 (95% CI = 2.401-6.608) times 
more likely to have IADL difficulties than participants without excessive polypharmacy, 
adjusting for all other confounders.  
 
Baseline predictor variable Adjusted OR 95% CI  p-value  
Polypharmacy 2004 (ref= 0-4 Rx)   
   
0.7924 
    Polypharmacy (5-9 Rx) 1.101 0.787 1.539  
    Excessive Polypharmacy (≥10 Rx) 1.174 0.517 2.662  
Polypharmacy 2008 (ref= 0-4 Rx)   
   
< 0.0001 
    Polypharmacy (5-9 Rx) 2.550 1.663 3.909  
    Excessive Polypharmacy (≥10 Rx) 4.679 2.704 8.096  
Age (ref=65-74 years) 1.547 1.024 2.339 0.0387 
Self-reported health (ref=excellent)    < 0.0001 
   Very Good  1.930 0.714 5.219  
    Good  3.573 1.336 9.558  
    Fair  8.286 3.040 22.586  
    Poor  13.690 4.266 43.932  
Arthritis  2.147 1.328 3.468 0.0024 
Psychiatric conditions  2.247 1.444 3.496 0.0006 
Cognitive impairment  3.452 1.174 10.146 0.0251 
Goodness-of-Fit Test p= 0.7038, N= 1359 and 186 missing observations were deleted 
  
81 
 
Table 4.32: Final model 11 for longitudinal analysis of IADL at endline and controlling for 
baseline functional-related variables and polypharmacy and excessive polypharmacy at 
baseline 
Baseline predictor variable Adjusted OR 95% CI  p-value  
Polypharmacy 2004 (ref= 0-4 Rx)   
   
0.4160 
    Polypharmacy (5-9 Rx) 1.280 0.877 1.868  
    Excessive Polypharmacy(≥10 Rx) 0.945 0.430 2.077  
Age (ref=65-74 years) 2.710 1.871 3.926 < 0.0001 
Self-reported health (ref=excellent)    < 0.0001 
   Very Good  1.162 0.457 2.954  
    Good  1.284 0.458 3.600  
    Fair  3.043 1.215 7.620  
    Poor  6.043 2.435 14.999  
Arthritis  1.667 1.099 2.527 0.0171 
Stroke  2.312 1.383 3.866 0.0019 
Depression  1.694 1.039 2.762 0.0351 
Alcohol drinking  0.547 0.391 0.766 0.0007 
Goodness-of-Fit Test p=0.6563, N= 1543 and 2 missing observations were deleted 
 
 
Table 4.33: Final model 12 for longitudinal analysis of IADL at endline and controlling for 
baseline functional-related variables and polypharmacy and excessive polypharmacy at 
baseline and at endline 
Baseline predictor variable Adjusted OR 95% CI  p-value  
Polypharmacy 2004 (ref= 0-4 Rx)   
   
0.2021 
    Polypharmacy (5-9 Rx) 1.400 0.959 2.042  
    Excessive Polypharmacy(≥10 Rx) 1.267 0.621 2.584  
Polypharmacy 2008 (ref= 0-4 Rx)      < 0.0001 
    Polypharmacy (5-9 Rx) 2.123 1.458 3.091  
    Excessive Polypharmacy(≥10 Rx) 3.673 2.041 6.608  
Age (ref=65-74 years) 2.448 1.679 3.570 < 0.0001 
Self-reported health (ref=excellent)    < 0.0001 
   Very Good  1.484 0.466 4.724  
    Good  1.440 0.431 4.816  
    Fair  3.187 1.096 9.268  
    Poor  6.659 2.192 20.226  
  
82 
 
Baseline predictor variable Adjusted OR 95% CI  p-value  
Arthritis  1.606 1.037 2.489 0.0344 
Stroke  1.945 1.072 3.528 0.0293 
Alcohol drinking  0.534 0.357 0.799 0.0029 
Goodness-of-Fit Test p= 0.5119, N= 1360 and 185 missing observations were deleted 
 
 
Sensitivity Analysis (2) 
In this analysis, the continuous form of ADL and IADL score were used. Also, number of 
medications was used as a continuous measure. Collinearity check was done for all continuous 
variables. Multiple linear regression model was used in this analysis. The first regression model 
will adjust for the baseline (2004) functional-related variables and number of medications at 
baseline. The second model will be the same with the addition of number of medication at the 
endline (2008). Each of the two models was done to each of the continuous ADL and IADL 
scores at endline.  
The weighted mean for ADL at baseline was 0.186 ± 0.637, and at endline 0.294 ± 0.875.  
The weighted mean for IADL at baseline was 0.129 ± 0.475, and at endline 0.249 ± 0.793. 
Higher score indicates greater disabilities. The weighted mean for number of prescription 
medications at baseline was 3.979 ± 3.256, and at endline 4.340 ± 3.572.  
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Table 4.34: Final model 13 for linear regression model of ADL at endline and controlling 
for baseline functional-related variables and number of medications at baseline  
Baseline predictor variable Estimate Standard 
Error 
p-value  
Age  
   65-74 years 
 
Ref. 
 
Ref. 
 
   75+ years  0.2553 0.0483 <0.0001 
Number of medications (2004) 0.0033 0.0063 0.6041 
Light exercise  
    Everyday 
 
Ref. 
 
Ref. 
0.0023 
    > 1 per week 0.1469 0.0848 0.0831 
    1 per week 0.1122 0.0899 0.2118 
    1-3 per month 0.1221 0.1187 0.3036 
    Never  0.4210 0.1120 0.0002 
Self-reported health   
    Excellent 
 
Ref. 
 
Ref. 
<0.0001 
    Very Good  -0.0155 0.0729 0.8317 
    Good  0.0773 0.0729 0.2885 
    Fair  0.3362 0.0816 <0.0001 
    Poor  1.1755 0.1145 <0.0001 
Obese 0.1390 0.0482 0.0039 
Depress 0.1416 0.0678 0.0367 
Arthritis  0.1300 0.0434 0.0027 
Goodness-of-Fit Test p= 0.6361    
 
Number of medications at baseline was not significant (p=0.6041) in final regression 
model for ADL as an outcome (Table 4.34). Baseline characteristic: age, SRH, light exercise, 
obesity, depression, and arthritis were all significant predictor for ADL difficulties at endline. 
Adding the number of medications at endline resulted in significant outcomes, for each unit 
increases in number of medications at endline the ADL score increases by 0.0432. (Table 4.35) 
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Table 4.35: Final model 14 for linear regression model of ADL at endline and controlling 
for baseline functional-related variables and number of medications at baseline and endline 
Baseline predictor variable Estimate Standard 
Error 
p-value  
Age  
   65-74 years 
 
Ref. 
 
Ref. 
 
   75+ years  0.2549 0.0475 <0.0001 
Number of medications (2004) 0.0038 0.0062 0.5386 
Number of medications (2008) 0.0432 0.0060 <0.0001 
Light exercise  
    Everyday 
 
Ref. 
 
Ref. 
0.0088 
    > 1 per week 0.1356 0.0834 0.1040 
    1 per week 0.1039 0.0884 0.2402 
    1-3 per month 0.0954 0.1168 0.4141 
    Never  0.3746 0.1104 0.0007 
Self-reported health  
    Excellent 
 
Ref.  
 
Ref. 
<0.0001 
    Very Good  -0.0451 0.0718 0.5299 
    Good  0.0113 0.0722 0.8755 
    Fair  0.2300 0.0816 0.0048 
    Poor  1.0320 0.1143 <0.0001 
Obese 0.0926 0.0479 0.0530 
Depress 0.1272 0.0667 0.0565 
Arthritis  0.1030 0.0428 0.0162 
Goodness-of-Fit Test p= 0.6155    
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Table 4.36: Final model 15 for linear regression model of IADL at endline and controlling 
for baseline functional-related variables and number of medications at baseline  
Baseline predictor variable Estimate Standard 
Error 
p-value  
Age  
   65-74 years 
 
Ref. 
 
Ref. 
 
   75+ years  0.3064 0.0439 <0.0001 
Number of medications (2004) 0.0077 0.0058 0.1830 
Self-reported health  
   Excellent  
 
Ref. 
 
Ref. 
<0.0001 
   Very Good  -0.0048 0.0670 0.9426 
    Good  0.0126 0.0669 0.8511 
    Fair  0.1910 0.0741 0.0099 
    Poor  0.7495 0.1021 <0.0001 
Arthritis  0.0967 0.0398 0.0152 
Cognitive impairment 0.7074 0.1641 <0.0001 
Stroke  0.3182 0.0777 <0.0001 
Alcohol drinking  0.1026 0.0389 0.0083 
Goodness-of-Fit Test p= 0.5465    
 
 Table 4.37: Final model 16 for linear regression model of IADL at endline and controlling 
for baseline functional-related variables and number of medications at baseline and endline 
Baseline predictor variable Estimate Standard 
Error 
p-value  
Age  
   65-74 years 
 
Ref. 
 
Ref. 
 
   75+ years  0.3127 0.0435 <0.0001 
Number of medications (2004) 0.0078 0.0058 0.1742 
Number of medications (2008) 0.0313 0.0056 <0.0001 
Self-reported health 
   Excellent  
 
Ref. 
 
Ref. 
<0.0001 
   Very Good  -0.0251 0.0664 0.7058 
    Good  -0.0368 0.0668 0.5817 
    Fair  0.1119 0.0747 0.1339 
    Poor  0.6418 0.1030 <0.0001 
Arthritis  0.0741 0.0396 0.0616 
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Baseline predictor variable Estimate Standard 
Error 
p-value  
Cognitive impairment 0.7320 0.1626 <0.0001 
Stroke  0.2553 0.0778 0.0010 
Alcohol drinking  0.0955 0.0385 0.0132 
Goodness-of-Fit Test p= 0.5359    
 
In the final regression model, the number of medications at baseline was not significant 
(p=0.1830) for IADL as an outcome (Table 4.36). Baseline characteristic: age, SRH, arthritis, 
cognitive impermanent, stroke, and alcohol drinking were all significant predictor for IADL 
difficulties at endline. Adding the number of medications at endline resulted in significant 
outcomes, for each unit increases in number of medications at endline the IADL score increases 
by 0.0313. (Table 4.37). 
The sensitivity analyses showed similar results to logistic models done in the previous 
section. Polypharmacy or number of medications were important predictors in all models looking 
at the relationship over time and which had polypharmacy at the endline. Categorizing the 
number of medications was more clinically applicable. Also, categorizing ADL and IADL were 
easier to interpret the result for clinical sittings. However, continuous measures gives more 
information, and it is more sensitive to changes. It needs a smaller sample size and it give variety 
of analysis options.  
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Aim 4: To identify potential confounders of the relationship between polypharmacy and 
functional status 
Aim 4-A): To assess the role of chronic conditions in the relationship between 
polypharmacy and functional status  
Each of the chronic conditions and the number of chronic conditions was examined in 
both cross-sectional and longitudinal models and were adjusted. The number of chronic 
conditions was significant in bivariate analyses. However, it was not significant in the 
multivariable models. Regarding each chronic condition, some of them, like arthritis and 
psychiatric conditions, were significant in most of the multivariable models. Other chronic 
conditions, like cancer, were not significant. In conclusion, some chronic conditions were 
considered important confounders to the relationship between functional status and 
polypharmacy.  
Aim 4-B) To identify potential confounders or modifiers of the relationship between 
polypharmacy and functional status 
All of the previous analyses in Aims 2 and 3 were performed to identify potential 
confounders and/or modifiers. Multiple interaction terms were included to identify effect 
modifiers. Those interactions included interactions between: self-reported health and 
polypharmacy, self-reported health and each chronic condition, and each chronic condition and 
polypharmacy. However, none of the interactions were significant. All of the significant study 
variables are confounders, and they change the relationship between polypharmacy and 
functional status in community-dwelling older adults.   
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Correlation between ADL and IADL 
 The Pearson Correlation Coefficients was 0.569 at baseline and 0.653 at endline. This 
means there is moderate correlation between ADL and IADL and it may measure similar thing 
but not exactly the same. It is known that ADL focus more on the physical activities of daily 
living and IADL focus in more complex aspects of instrumental activities of daily living. This 
explains the moderate correlation we see between ADL and IADL. We need both to get a better 
understanding of functional decline.  
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Chapter 5 Discussion 
 
 
 
5.1 Descriptive data discussion  
This study showed that polypharmacy was significantly associated with functional 
decline in cross-sectional and longitudinal analyses. A stronger association was found at the end 
of the study. Our results are similar to others studies that examined the association between 
functional status and polypharmacy (Jay Magaziner et al. 1989; Jyrkkä et al. 2011b; Lau et al. 
2011). Other confounders were also important such as self-related health, age, and arthritis in the 
longitudinal analyses. In all cross-sectional analyses self-reported health and light exercise were 
also associated with functional status. The baseline demographics reported in this study are 
similar to those reported in other studies using the same HRS and PDS files (Zivin et al. 2009; 
An and Lu 2015). In Table 4.1, we can recognize that 16.2% of participants reported ADL 
difficulties and 13.8% of participants reported IADL difficulties in 2008. Both percentages 
increased 4.7% from 2004 to 2008. ADL difficulties were slightly more common than IADL 
difficulties. A similar trend was observed in a study using the same HRS dataset waves, and 
showed that ADL difficulties were reported slightly higher than IADL difficulties (An & Lu 
2015). Overall, the proportion of the population reporting functional limitations was low in our 
study population compared to other studies like the National Health and Aging Trends Study 
which reported that 48.3% of participants experienced difficulty and received help from another 
person with ADL (Freedman & Spillman 2014). Under-reporting of functional limitations is 
common in community-dwelling older adults until it is no longer tolerable, , and it may be 
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attributable to the threat of loss of independence (Guccione et al. 1994; Fried and Guralnik 
1997). Other explanations for under-reporting are participants may limit the frequency of doing a 
duty to the minimum essential effort, or sometimes increase the frequency of a task but do less 
work at any one time. Also, they could change the way they do the task to minimize the effort, 
for example, lean on the shopping cart and report no difficulties (Fried and Guralnik 1997; Saliba 
et al. 2000). Our study population was also relatively healthy, as most of them reported very 
good to good health status. It is interesting to mention that older adults often interpret self-
reported health (SRH) in general as their health compared to other people of similar age, which 
means that they might have some health issues but considering their age they think they are 
healthy (Chen et al. 2016). Also, a non-polypharmacy group is three times more likely to report 
good SRH than a polypharmacy group (Agbor et al. 2013). In our study, we have more non-
polypharmacy than polypharmacy participants compared to this study. 
The prevalence of polypharmacy was similar to what was reported in the literature. It was 
reported in previous studies that the prevalence of older adults taking more than five medications 
is 36% to 39% (Charlesworth et al. 2015; Levy 2017). In our study, 35.9% reported 
polypharmacy status, and it increased to 40.7%. One potential reason for this increase in our 
study population was that Medicare Part D for prescription drug coverage had been 
implemented. Atorvastatin was the most common medication used in the study. It is also the 
most commonly used statin worldwide (Patel et al. 2013). Statins are prescribed to prevent 
cardiovascular diseases and lowering cholesterol levels. Statins side effects can include muscle 
weakness and fatigue. A randomized control study showed a relation between statin usage and 
fatigue which could lead to functional decline (Golomb et al. 2012). In our study, we only tested 
one medication from the statins class, which was Atorvastatin, as a confounder, but the results 
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were not significant. One study in Australia reported a low statin–drug interactions and that 
statins do not interact with many other medications which could explain the non-significant 
results we had in our results (Thai et al. 2015). However, we cannot rule out that there is no 
association between all statins as a class of drug and functional decline and further studies to 
look at the relation between statins and functional status is recomended. The HRS does not have 
enough information about drug classes and each participant was asked to write a list of all the 
medications prescribed, including those taken occasionally. And if they were more than ten 
medications, then participants choose what he/she consider the most important. So, we cannot 
tell if the participants were taking statins or not. Another explanation might be that the 
relationship between polypharmacy and functional status is not simply due to the use of drugs 
like statins whose side effects (muscle weakness, fatigue) in older adults but due to using a large 
number of medications together.  
About 70% of participants used drug chain stores, mail orders pharmacies, and 
independent pharmacies as the source of getting their prescribed medications. One study reported 
that drug chains and independent pharmacies accounted for 40% and 35% of all pharmacies in 
the US (75% in total), which is consistent with the most common source identified in this study. 
Different types of insurances were also used, and 55% of participants paid some of the costs of 
their prescribed medications and the insurance paid the rest. Having governmental insurance or 
prescription drug coverage were not significant as variables affecting the relationship between 
polypharmacy and functional outcomes in all the bivariate analysis and longitudinal models. 
Our study showed we had 13 non-responses in the endline, which were deleted from the 
study. All the non-responses were code 4, meaning that the participants were alive as far as we 
know but did not respond. It is important to look at non-responders, especially if they were 
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deceased because the results might then be attenuated. Since our non-responders were alive and 
their sample size is very low, then deleting them should not affect our results significantly. 
 
5.2 Functional status and polypharmacy in cross-sectional analyses 
Looking at the cross-sectional models, we can conclude that polypharmacy was an 
important predictor for ADL in both bivariate and multivariable analyses. After controlling for 
confounders, the odd ratio between polypharmacy and ADL increased from 2004 to 2008, 
OR2004 = 1.4 (p = 0.0256) and OR2008 = 1.9 (p = 0.0044). After 4 years, participants with 
polypharmacy were almost 90% more likely to report ADL difficulties than non-polypharmacy 
participants, compared to the beginning of the study where the participants with polypharmacy 
were 40% more likely to report ADL difficulties than non-polypharmacy participants. For IADL, 
both the adjusted and unadjusted analyses at the baseline did not show an association between 
IADL and polypharmacy status (adjusted OR2004 = 1.2; p = 0.5080). However, in 2008 the 
association became significant (p = 0.0216), and the OR increased to OR2008 = 1.7. Similar 
results for IADL decline after 3 years were also described in Jyrkka et al (Jyrkkä et al. 2011b). 
The change in the association from not significant to significant and the rise in the OR might be 
due to Medicare Part D implementation and the availability of prescription drug coverage. In 
2006, Medicare Part D was implemented and provided prescription drug coverage for older 
adults through private health plans. This coverage could lead to increased polypharmacy status 
leading to a decline in IADL. One study reported similar results demonstrating a stronger 
association between ADL decline and polypharmacy and significant but a weaker association 
between IADL and polypharmacy (Jay Magaziner et al. 1989). Marital status could be another 
explanation, as we noticed 7.6% of married people in 2004 became widowed by 2008. IADL 
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include food preparation, shopping, medication administration, using the telephone, and 
managing money. Those listed items in IADL could be performed with the help of a caregiver. 
However, the number of people living in the same house, and marital status were not a 
significant predictor for functional decline in the adjusted analyses. Our results are similar to the 
cross-sectional study discussed in the literature review chapter. Connolly et al. reported a 
stronger relationship between ADL and polypharmacy than IADL and polypharmacy (Connolly 
et al. 2017). 
5.3 Confounders in cross-sectional analyses  
The confounder is a variable that influences both the outcome (functional status) and the 
exposure (polypharmacy) causing a false association. In order to be a confounder, it needs to be a 
risk factor for both exposure and outcome and not to be in the causal pathway. We can identify 
potential confounders from previous knowledge, common sense, or meeting the three criteria 
listed above.   
In the adjusted cross-sectional analyses, self-reported health (SRH) and light exercise 
were the two variables that were present in all cross-sectional models for both outcomes ADL 
and IADL.  Self-reported health was also recognized in the literature to be a significant predictor 
of negative outcomes including functional decline and mortality (Fonta et al. 2017; Cesari et al. 
2008). The poorer the SRH, the more medications are prescribed. Therefore, it influences both 
number of medications and functional decline. Regular exercise, ranging from light to vigorous, 
has been shown to decrease the risk of mortality and negative health outcomes including 
disability (Fonta et al. 2017). Interaction terms between SRH and polypharmacy and other 
chronic conditions were conducted, and none were significant. For exercise, it is well established 
that a sedentary lifestyle can increase the risk of heart disease, stroke, and functional limitations. 
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Increasing the number of comorbid conditions will also increase the number of prescribed 
medications and thus polypharmacy status. It is important to mention that exercise can reverse 
some of the health consequences when individuals start to exercise regularly (Rosenkranz et al. 
2013).  
Also, in the ADL and IADL cross-sectional analyses we can realize that psychiatric 
conditions were included in the final model in 2004; however, the p-value was < 0.10 and higher 
than our significance level of 0.05. The psychiatric conditions in 2004 for ADL and IADL had a 
p = 0.0891 and p = 0.0629 respectively. While in 2008, the psychiatric disorders for ADL and 
IADL had a p = 0.0056 and p = 0.0017 respectively. The psychiatric condition is a mental illness 
diagnosed by a mental health professional, and it affects mood, behavior, and thinking abilities. 
It can cause great harm to the person's life leading to disability and death. Since functional status 
needs both physical and mental ability, the presence of psychiatric problems could disturb a 
person's ADL and IADL. It has been shown that there is a relationship between psychiatric 
disorders and decline in both ADL and IADL (Kivelá & Pahkala, 2001; Mograbi et al. 2017). 
Likewise, persons with psychiatric conditions tend to have more prescribed medications than 
those who have not been diagnosed with a psychiatric condition (Lau et al. 2011). Since 
depression is often a part of psychiatric disorder, an interaction term between psychiatric 
conditions and depression was evaluated, and it was not significant. 
We observed that the final models for ADL in 2004 and 2008 were similar and had 
similar predictors. In addition to polypharmacy, SRH, and light exercise (and psychiatric 
conditions in 2008), we noticed that obesity and depression were present in all cross-sectional 
analyses with ADL difficulties as an outcome. There are many longitudinal and cross-sectional 
studies that reported the association between ADL disabilities and obesity, and a limited number 
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of studies reported the association between IADL disabilities and obesity (Okamoto et al. 2018; 
Cesari et al. 2008;  Himes 2000). A study that used HRS as the data source also showed that 
obesity, defined as BMI  ≥ 30 kg/m2, was associated with ADL decline (Sturm et al. 2004). 
Obesity prevalence in older adults is increasing, and is linked to many factors including 
sedentary lifestyle, change in metabolic rate, and change in diet (Arteburn 2004). Obesity is 
linked to many comorbid conditions including heart disease and cancers. It has been 
hypothesized that obesity and big body size could be linked to a decline in functional status by 
limiting mobility. The excess weight can also affect joint flexibility, decrease muscle strength, 
and reduce the capacity to exercise. Another study hypothesized that obesity would increase the 
risk of chronic conditions and thus it will increase both the number of prescribed medications 
and functional decline (Gibbs et al 2005). For depression, it has been reported that there is an 
association between depression and functional decline, but it is not clear whether the depression 
leads to functional decline, or if the functional decline leads to depression (Zivin et al. 2009; 
Mograbi et al. 2017; Kivelá and Pahkala 2001). Depression also increases the number of 
prescribed medications. The long term use of antidepressant medications is also associated with 
functional decline (An & Lu 2016). 
In the final model for IADL at 2004 and 2008, wealth was an important confounder. It is 
well documented that low socioeconomic status is associated with poor health, disability, and 
premature mortality (Torres et al. 2016). Higher economic status allows individuals to have 
better access to healthcare facilities and medications. Moreover, individuals with a higher 
economic status are more likely to have good social support, spouses, and more friends. Torres et 
al. showed a negative relationship between wealth and difficulties in ADL and IADL. 
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Some additional confounders were found in the IADL or ADL final model. Arthritis was 
an important risk factor in the final model of ADL difficulties in 2008. Arthritis was also in the 
final model of ADL difficulties in 2004; however, it was not significant (p = 0.0598). Patients 
with arthritis are more likely to have functional disabilities (Marques et al. 2016). Arthritis is 
also associated with polypharmacy in long-term care facilities (Jokanovic et al. 2015). Gender 
was also included in our final model for IADL in 2008. Many studies have identified that 
females are more likely to have polypharmacy and are at higher risk of polypharmacy 
consequences since body fat increases as a part of aging in females to a greater extent than males 
(Jay Magaziner et al. 1989). Also, females are more likely to take prescribed medications. They 
are also more likely to report poor SRH and disability (Fonta et al. 2017).  
Alcohol drinking also appeared in the final cross-sectional model for IADL in 2004. 
Those who drink alcohol were 70 % as likely to report IADL difficulties than nondrinkers. 
Similar results were also found in a systematic review. Many studies in the review found that 
nondrinkers are at higher risk for functional difficulties compared to moderate drinkers (Stuck et 
al. 1999). In addition, individuals with poor health might stop drinking, and that might explain 
these results. Heavy drinkers, on the other hand, are at greater risk of functional decline and 
drinking increases the risk of drug interactions. Alcohol concentration is higher in older adults 
for the same amount consumed in younger adults because of the change of body composition 
with more body fat and less body water (Delafuente 2008). Additionally, heart conditions 
appeared in the final cross-sectional model for IADL in 2004, and they are a well-known risk 
factor for polypharmacy. Patients with angina and myocardial infarction will be automatically on 
at least 5 prescribed medications according to practice guidelines (Schwinger 2018; Jokanovic et 
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al. 2015). Heart conditions are also a risk factor for functional decline as reported in Stuck et al. 
1999. 
5.4 Functional status and polypharmacy in longitudinal analyses 
 In the adjusted models looking at the four-years (2004-2008) relationship between 
polypharmacy and our main outcomes ADL and IADL, we noted that polypharmacy status at 
baseline (2004) was not an important predictor for functional decline (model 1 and 3); however, 
adding polypharmacy status for the endline (2008) was an important predictor (model 2 and 4). 
The odds for reporting ADL and IADL decline in 2008 were 2.4 (95% CI = 1.666-3.570) and 2.1 
(95% CI = 1.460-2.872) times more likely in participants with a 2008 polypharmacy status.  
Looking at the two-year (2006-2008) relationship between polypharmacy and functional 
status, we recognized that polypharmacy status before 2 years was important (ADL p = 0.0138, 
IADL p = 0.0636 [borderline significance]) (model 5 and 7). When adding polypharmacy status 
for the endline (2008) to model 6 and 8, polypharmacy status at 2006 was no longer significant 
(ADL p = 0.5731, IADL p = 0.6029). This means that polypharmacy status of the same period 
was more important than two years prior. This result is similar to that observed in another study 
that concluded that polypharmacy cannot predict functionality over a three-years period (Jyrkkä 
et al. 2011b). Polypharmacy of the same year was significant in almost all cross-sectional models 
with one exception (discussed above), and in all longitudinal models which had polypharmacy at 
the endline as a predictor. As a result, we can conclude that polypharmacy is an important 
predictor of functional decline and it might not have the long-term relationship (4 years) but 
rather two years or less. It interrupts participant’s functional status around the same period rather 
than contributing to future decline. This might be due to the acute effects of drug-drug 
interactions, or PIMs. Patient could have been in poor health or experienced a health event that 
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led to an increase in prescribed medications and eventually functional decline. Also, the low 
number of prescribed medications used by most participants in HRS (participants with 
polypharmacy were fewer than participants with no polypharmacy) could contribute to the lack 
observation of a long-term relationship. We also had a low percentage of participants who 
reported functional decline and our population were mostly healthy, which could also contribute 
to not seeing a long-term relationship. Previous studies that showed long-term relationships had 
more participants with polypharmacy than in our study and they included OTC medications to 
determine polypharmacy status. Our study did not include OTC medications, which is an 
important factor for the number of medications, especially if they are being taken regularly. Not 
including OTCs is one of our study limitations. Also, the populations of previous studies had 
more health conditions with more participants reporting poor SRH. In addition, we did not 
exclude participants with functional decline at the baseline, this gave us different starting points 
for our participants and might influence the results.  
 In the observed association between polypharmacy and functional decline after 2 and 4 
years the number of medication itself may not be the cause, but rather it is a contributing cause 
where the benefits may outweigh the risks for some patients and vice versa.  Functional decline 
also occurs in the absence of polypharmacy. This suggests that polypharmacy may be a good 
predictor or indicator for early detection of functional decline.  
5.5 Confounders in longitudinal analyses  
Age, SRH, and arthritis were confounders in all the adjusted longitudinal analyses for 
both outcomes ADL and IADL. Age is a well-known risk factor for both functional decline and 
polypharmacy. 19.4% of our participants had a shift in age categories from 65-74 years to 75+ 
years during the 4 years (Table 4.1).  Aging is associated with physiological changes that include 
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decreased hepatic and renal function, changes in body composition, decline in baseline 
performance and decreased homeostatic reserve. These physiological changes can cause changes 
in drug pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacodynamics (receptor and drug action on the body) often resulting in increased drug 
exposure and exaggerated drug (Bushardt et al. 2008; Jokanovic et al. 2015).  SRH is the only 
confounder that was present in all models (cross-sectional and longitudinal). This supports the 
idea that functional status reflects the health status and independency of people. SRH seems to be 
a very important predictor, and this means that we should pay attention to participants reporting 
fair or poor health and having polypharmacy because they are at higher risk of reporting 
functional decline. In this case, we can see polypharmacy as a risk factor, and managing 
prescribed medications for patients who report fair to poor health as mandatory. On the other 
hand, for patients reporting excellent and good health status, polypharmacy might be appropriate 
with no need for modification. Multiple medications do not always have to be problematic ( 
Levy 2017). Some older adults are on multiple medications, and they are healthy, while others 
would be in better health if their medications were fewer.  Regardless, it is important to ensure 
that for all medications the benefits outweigh the risks for the individual patient. 
 Regarding the longitudinal models with ADL as the main outcome, obesity and 
psychiatric conditions were the additional confounders that presented in all longitudinal models, 
whereas the IADL model had stroke as a confounder. Stroke affects the neuromuscular system 
and could affect the functional status depending on the prognosis and severity. Stroke was found 
in the Framingham study to be the most strongly associated with grocery shopping dependence 
(Guccione et al. 1994). Shopping is one of the items in IADL, and so this could be the 
explanation of the IADL decline associated with stroke observed in our study. Lastly, cognitive 
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impairment was a confounder for the association between ADL and polypharmacy in Models 1 
and 2 (4 years association). In our study, cognitive impairment was associated with ADL decline. 
Cognitive impairment has been shown to be related to polypharmacy (Silay et al. 2017). Also, 
functional decline is associated with cognitive impairment (Ho et al. 2018).  
Since functional decline is reversible in some cases and polypharmacy could be adjusted 
and monitored to give better outcomes, then we should pay attention to the modifiable risk 
factors we found in our study (alcohol use, exercise, BMI) along with a prescribed medication 
checkup. Monitoring risks factors for functional decline could change patient status from 
dependent to independent or at least slow the progression of functional decline.  
 
5.6 Strength and limitation  
Using a nationally representative dataset not previously evaluated was a strength to our 
study. Another strength was controlling for some chronic conditions and the number of chronic 
conditions. Both cross-sectional and longitudinal analyses were conducted in our study to better 
understand the relationship. Looking at multiple time points and providing a sensitivity analysis 
which looked at excessive polypharmacy strengthened our study.  
One major limitation of this study is the use of self-reported data. The accuracy of self-
reported information is dependent on a variety of factors including participants’ understanding of 
the questions, willingness to be honest with the interviewer about potentially embarrassing topics, 
bias towards providing socially-desirable responses, and mood and mental status at the time of 
interview. Despite controlling for many confounders in our observational study, we cannot 
eliminate the confounding bias due to non-randomized design of our observational study, and thus 
our result is association rather than causation.  
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Another limitation is the inclusion of only those participants with complete functional and 
medication data at both baseline and endline, which limited our study population. Other limitations 
of this study include a lack of data on health conditions other than the eight chronic diseases 
included in the HRS, the severity of the chronic conditions mentioned in the "Measures" section 
and a lack of information about over-the-counter medication use. It is also not possible to examine 
the use of potentially inappropriate medication because this would require an individual 
assessment of each participant's prescription list and health history. The generalizability of this 
study is limited to community-dwelling adults in the United States, and findings may not apply to 
institutionalized adults or adults in other countries. 
Finally, an important limitation is the time when the data was collected, more than 10 years 
ago.  Prevalence of polypharmacy, access to healthcare and other factors may have changed during 
the past ten years.  This dataset remains a valuable resource to assess the relationships between 
polypharmacy and functional status however.    
5.7 Conclusion 
Polypharmacy is a good predictor or indicator for early detection of functional decline. 
Polypharmacy status of the same year showed a significant association with functional decline in 
cross-sectional, and in all longitudinal models which had polypharmacy at the endline as a 
predictor. Many confounders were found to be significant. SRH and light exercise were 
associated with functional decline in all cross-sectional analyses. SRH, age and arthritis were 
important confounders for the longitudinal analyses.  
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5.8 Future directions 
 
Since both polypharmacy and functional decline are modifiable and preventable, then it 
would appropriate to conduct additional observational studies (prospective cohort) and look for 
possible reasons behind the observed association, confirm the observed association, and try to 
overcome the limitations in the studies to date. Future studies should enroll participants with no 
functional decline at the beginning of the study, follow them over time, gather information 
regarding prescribed and OTC medications taken regularly, and record detailed information 
regarding dosage, frequency, indication of prescriptions, side effects, and any special instruction. 
The medications should be checked by pharmacists for PIM including medications on the Beer’s 
list, drug-drug interactions, drug-disease interactions, duplications, inappropriate dosing, and 
unnecessary medication (no indication for usage). Also, access to participants’ medical records 
to check for an appropriate indication of the medications would be valuable. The severity of 
participants’ chronic illness should be accounted for as well. 
Our study would help health care providers and policy makers target at risk populations 
for interventions and help older adults maintain independence. Future studies examining specific 
medication classes and their relationship to functional decline could help in designing 
interventions. Also, implementing an intervention study for de-prescribing, or intensive 
medication review to evaluate functional status as an outcome would help to better understand 
this relationship.   
Our study may also have implications for the annual Medicare Wellness Visit that is part 
of Medicare Part B.  During the first Medicare Annual Wellness Visit (AWV) 
(medicareinteractive.org), the following should be assessed:  
1) Height, weight, blood pressure, and other routine measures. 
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2) Health risk assessments about health status, injury risks, behavioral risks, and urgent 
health needs. 
3) Functional ability of ADL and level of safety (includes risk of falling, and level of 
safety) 
4) Medical and family history 
5) Current prescription medications, as well as vitamins and supplements, and durable 
medical equipment (DME) suppliers. 
6) Cognitive impairment, including diseases such as Alzheimer’s and other forms of 
dementia 
7) Depression 
Based on this assessment, the provider should create a written 5-10 year screening schedule 
or check-list as well as provide appropriate health advice and referrals to health education 
and/or preventive counseling services aimed at reducing identified risk factors and promoting 
wellness which includes: weight loss, physical activity, smoking cessation, fall prevention, 
nutrition, and more.  
The following visit will be conducted according to patients’ needs and written plan. The 
annual visit is very good opportunity to address issues around polypharmacy and functional 
status in older adults. Based on our study, considering polypharmacy, functional status, and other 
confounders I propose the following approach to incorporate our findings into patient care 
(Figure 5.1): 
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1) If the patient is between 65 and 74 years of age, has no difficulty in both ADL and IADL, 
no polypharmacy, or SRH is excellent-good, then there is no need for intervention, and 
follow up can occur after one year. 
2) If the patient is 75 years or older, has difficulty in ADL, has difficulty in IADL, has 
polypharmacy, or SRH is fair-poor, then full medication review is recommended, along 
with assessing for modifiable risk factors and controlling chronic conditions, and 
individualize an appropriate intervention to reduce risk. 
  This could be incorporated into the annual visit by identifying participants who need 
immediate attention, and others who can be seen in the following year. Also, once identifying the 
risk group, a full medication review is recommended to identify PIMs, medications to avoid in 
Beer’s list and drug-interactions. Moreover, a full medical history and lab work for chronic 
conditions should be performed to guide better management of chronic disease. 
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Figure 5.1 Guidelines for standard care in community-dwelling older adults   
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Appendix 
 
  
Table A: Medications drug survey data variables (2005 and 2007 PDS, and 2009 HWB) and 
SAS code 
Variable/ Name 
before merge  
Name after merge Notes  Dataset PDS05 
Merge variables HHID, PN, POSITION  HHID and PN all 
sections, position 
section E 
Number of 
medications  
Pds05_medsintable 
 
Number scripts in 
table provided in the 
questionnaire 
Not in data, built 
during merge from 
section E. 
MAX(position)  
Name of medications  Pds05_P1DRUGNAME1  Drug name from 1 to 
10 
Not in data, built 
during merge from 
section E  
Medication brand 
name  
Pds05_1BRANDNAME Brand name from1-10   Not in data, built 
during merge from 
section E 
Medication: How long 
taking /P1E2 
Ppds05_duration 
 
Duration of use for 
each drug from 1to 10 
Section E 
# Prescribed 
medications in last 
month/P1A3 
Pds05_P1A3  Section A 
# Prescribed 
medications regularly 
/P1A4 
Pd05_P1A4/ Polybase  Categorized into 
Polypharmacy 
baseline <5 prescribed 
medications, ≥5 
prescribed medications 
Section A 
What type of 
pharmacy 
Pds05_P1A7A From A-J Section A 
Prescription drug 
coverage P1B1 
Pds05_P1B1 1.I pay some of the 
price and insurance  
2.  I get a small 
discount                          
3.  I pay full price for 
all medications  
4.  I don't pay 
anything. 
5.  Other 
Section A 
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Source of prescription 
insurance (yes/no by 
category)/P1b8a-g 
Pds05_p1b8 
 
Pds05_p1b8a -g Section A 
Any side effects Pds05_P1C2 SKIP=0  Section A 
Action in response to 
side effects (yes/no by 
category) 
Pds05_P1C3A-F  Section A 
Questionnaire by 
proxy/P1H1 
Pds05_P1H1  Section A 
Sample weights and 
completion status 
P1QX, P1MED, P1QXWT, 
P1QXMED 
 Section S 
Merge variables for 
PDS07  
HHID, PN, POSITION, 
POSITION_F 
 All sections (position 
only in section E and 
F) * 
# Prescribed 
medications regularly/ 
P2A4 
Pds07_P2A4/polymed Categorized into 
Polypharmacy middle 
<5 prescribed 
medications,  ≥5 
prescribed medications 
Section A* 
Prescription drug 
coverage /P2B1 
Pds07_ P2B1 1.I pay some of the 
price and insurance  
2.  I get a small 
discount                          
3.  I pay full price for 
all medications  
4.  I don't pay 
anything. 
5.  Other 
Section A* 
Merge variables HHID, PN  All sections (A and S) 
** 
# Prescribed 
medications regularly 
/P3A4 
 
Hwb09_P3A4/polyend Categorized into 
Polypharmacy end line 
<5 prescribed 
medications, ≥5 
prescribed medications 
Section A** 
Prescription Drug 
coverage/P3A1B 
hwb09_P3A1B Yes, no  Section A** 
* PDS07 dataset    ** HWB09 dataset  
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Table B: Functional status variables and SAS codes  
Variable Name  Name after merge and coding Notes  Dataset 
ADL   Summary score 
were recoded into 
(yes, no) for having 
functional 
limitations and 
adlbase/adlmed/ 
adlend   
 
Summary 
score 
RwADLA R7ADLA/R8ADLA/R9ADLA  
Bathing RwBATHA R7BATHA/R8BATHA/R9BATHA RAND 
Dressing RwDRESSA R7DRESSA/R8DRESSA/R9DRESSA RAND 
Eating RwEATA R7ETA/R78EATA/R9EATA RAND 
Getting in 
or out of 
bed 
RwBEDA R7BEDA/R8BEDA/R9BEDA RAND 
Walking RwWALKRA R7WALKRA/R8WALKRA/R9WALK
RA 
RAND 
IADL   Summary score 
were recoded into 
(yes, no) for having 
functional 
limitations and 
Iadlbase/ 
Iadlmed/ 
Iadlend   
 
Summary 
score 
RwIADLA R7IADLA/R8IADLA/R9IADLA RAND 
Phone RwPHONEA R7PHONEA/R8PHONEA/R9PHONE
A 
RAND 
Money RwMONEYA R7MONEYA/R8MONEYA/R9MONE
YA 
RAND 
Medication 
Administra
tion 
RwMEDSA R7MEDSA/R8MEDSA/R9MEDSA RAND 
Shopping RwSHOPA R7SHOPA/R8SHOPA/R9SHOPA RAND 
Meals RwMEAL R7MEAL/R8MEAL/R9MEAL RAND 
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Table C: HRS study variables and SAS code  
Variable Name 2004/2006/2008  Dataset 
Age RwAGEY_B Age /age2_/age3_ Converted 
into 
categorical 
(65-74Y, 
75+Y) 
RAND 
Sex (male, 
female) 
RAGENDER RAGENDER  RAND 
Race (white, 
black, other) 
RARACEM Race  Non-Hispanic 
white  
Non-Hispanic 
black 
Others  
Hispanics 
RAND 
Hispanic (yes, no) RAHISPAN Race  RAND 
Education (years) RAEDYRS Edu   RAND 
Household income  HwITOT Wealth/wealth2_/wealth3_ Converted 
into 
categorical by 
quartiles  
RAND 
Number of people 
in house including 
respondent and 
spouse 
HwHHRES People/people2_/people3_ Converted 
into (alone, 2 
persons, more 
than 2) 
RAND 
Self -reported 
Health status 
(poor, good, 
excellent) 
RwSHLT 
 
R7SHLT/R8SHLT/R9SHLT   RAND 
Marital status 
(Married, 
divorced, 
widowed, never) 
 
RwMSTAT Mstat/mstat2_/mstat3_ I had to make 
a new 
recategorize 
for mstat4_ 
because never 
had 0 
participants 
RAND 
# household 
residents, 
including 
respondent and 
spouse 
HwHHRES   RAND 
Insurance status     
Government RwHIGOV R7HIGOV/R8HIGOV/R9HIGOV  RAND 
Employer RwCOVR R7COVR/R7COVR/R8COVR  RAND 
Spouse’s 
employer 
RwCOVS R7COVS/R8COVS/R9COVS  RAND 
Other RwHIOTHP R7HIOTHP/R8HIOTHP/R9HIOTHP  RAND 
# Health ins plans RwHENUM R7HENUM/R8HENUM/R9HENUM  RAND 
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Depression (yes, 
no) 
RwCESD Depress/depress2_/depress3_ Recoded to 
no if score ≤3 
or yes if >4  
RAND 
Cognitive 
impairment (yes, 
no) 
RwCOGTOT Cog/cog2_/cog3_ Recoded to 
no if score 
>10 or yes if 
≤10  
 
Obesity (yes.no) RwBMI Obese/obese2_/obese3_ Recoded to 
no if score 
<30 and yes 
if score≥30  
RAND 
Exercise     
Frequency 
vigorous 
1.Every day  
2.>1 per week  
3.1 per week  
4.-3 per month 
5.Never 
 
RwVGACTX R7VGACTX/R8VGACTX/R9VGACTX  RAND 
Frequency light 
1.Every day  
2.>1 per week  
3.1 per week  
4.-3 per month 
 
RwLTACTX 
 
 
  RAND 
Smoking  SOMKER/SOKER2_/SMOKER3_ It was 
recategorized 
into 1-current 
smoker 
2-former 
smoker 
3-never 
smoker  
 
Ever RwSMOKEV RAND 
Current RwSMOKEN RAND 
Alcohol (Yes, no) RwDRINK R7DRINK/R8DRINK/R9DRINK  RAND 
Chronic diseases     
Total number RwCONDE R7CONDE/R8CONDE/R9CONDE  RAND 
Hypertension RwHIBPE R7HIBPE/R8HIBPE/R9HIBPE  RAND 
Diabetes RwDIABE R7DIABE/R8DIABE/R9DIABE  RAND 
Cancer RwCANCRE R7CANCRE/R8CANCRE/R9CANCRE  RAND 
Lung disease RwLUNGE R7LUNGE/R8LUNGE/R9LUNGE  RAND 
Heart disease RwHEARTE R7HEARTE/R8HEARTE/R9HEARTE  RAND 
Stroke RwSTROKE R7STROKE/R8STROKE/R9STROKE  RAND 
Psychiatric RwPSYCHE R7PSYCHE/R8PSYCHE/R9PSYCHE  RAND 
Arthritis RwARTHRE R7ARTHRE/R8ARTHRE/R9ARTHRE  RAND 
Proxy interview RwPROXY R7ROXY/R8PROXY/R9PROXY  RAND 
Institutionalization 
status (living in 
nursing home or 
RwNHMLIV R7NHMLIV/R8NHMLIV/R9NHMLIV  RAND 
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health care 
facility) 
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